



SomnoMed[®]

The Leader In COAT[™]
(Continuous Open Airway Therapy)

2017 ANNUAL REPORT

TABLE OF CONTENTS

1	Chairman's Letter
2	CEO's Report
7	Directors' Report
20	Financial Reports
55	Auditor's Report
61	Additional Information

SOMNOMED LIMITED

CHAIRMAN'S LETTER

Dear SomnoMed Shareholder,

The financial year 2016/17 will be a year to remember. It was marked by significant changes, which will have a long term positive impact on our company.

On 1st of September 2016, our new Chief Executive Officer Mr Derek Smith took over the responsibility to manage our global business from me. Since then, Derek, based in Denver, Colorado, and eminently qualified to run a global medical device business, is making his mark on SomnoMed's business. His mission is to lead SomnoMed into, what we believe is, a very bright future.

Our new entity, Renew Sleep Solutions, Inc. ("RSS") started at the beginning of the year to develop a business providing direct to patient sleep apnea treatment services. RSS assembled a highly qualified team based in Dallas, Texas, put all central departments in place and opened our first seven treatment centres across the US in a span of only seven months.

Our US business navigated successfully adverse reactions to the RSS initiative from some of our US customers and returned to solid growth in the last quarter of the year. In 2017/18 and beyond, our SomnoMed North America is expected to show solid growth benefitting from the combination of a growing COAT™ business and supplying our RSS centres with SomnoDent® devices.

SomnoMed Europe showed accelerated growth last financial year. France and Belgium followed Holland, Sweden and Norway in regulating in favour of COAT™ and putting clear reimbursement directions in place. We expect several other countries to follow suit over the next few years, which will allow our European business to grow for years to come.

Finally, despite changes in our top management and difficult circumstances in the US for most of the financial year passed, our company managed to control its expenses well and deliver a 60% growth in our SomnoMed core business (excluding RSS) adjusted EBITDA*.

We are entering the financial year 2017/18 with great optimism. Combined revenues of our SOM and RSS businesses are expected to grow by some 50% over the next twelve months and earnings are expected to double.

Let me thank you, our shareholders, for your support and loyalty. We hope that you will agree with us in the future that the financial year 2016/17 was a historic year on SomnoMed's path to build a fast growing world class medical device and service company.

Yours sincerely,



Dr Peter Neustadt
Chairman

* EBITDA as adjusted does not include share and option expense, gain/(loss) on contingent consideration payable and impairment of goodwill

SOMNOMED LIMITED CEO'S REPORT

Dear SomnoMed Shareholder,

2016/17 was obviously a very big year for both the company and me personally. I joined the Company in September of 2017 with great optimism and having completed my first year with SomnoMed that optimism has only grown. The strategy, people, products and solutions that I inherited were all in good order, even if they had to further evolve and be improved upon, which is normal in a fast-growing business. The opportunity that SomnoMed has to provide people who suffer from Obstructive Sleep Apnea ("OSA") with an effective and more comfortable therapy which enhances their health and improves their lives is enormous. The opportunity to lead such an organisation with such a clear and worthy mission is a privilege. It is our full intent to not only bring relief to sufferers of OSA, but to make other key stakeholders successful in this endeavor, including of course our shareholders.

With the addition of RSS and our ongoing commitment to our Managed Care business which directly contracts with US insurers, SomnoMed's business is no longer focusing only on supplying practitioners and patients with SomnoDent oral appliances. It now aims to generate and process direct patient responses, to provide home sleep diagnoses, to treat patients in conjunction with sleep specialists and to assist with the processing of patients' insurance claims. As a result, SomnoMed's strategy has been expanded to cover the broader aspects of a Sleep Solution business, addressing the various needs of patients suffering from obstructive sleep apnea.

Business overview – a transitional year

The 2016/17 financial year can be clearly regarded as a transitional year, where we transitioned the leadership of the company, as well as executing on an expanded strategy. Our move to launch the Renew Sleep Solutions business, which attracts potential OSA patients via direct to consumer marketing and then provides a whole turnkey solution to OSA sufferers, was a huge initiative and transition for us. This new business was successfully launched in 2016/17, whilst we continued to make significant progress and showed good growth in our core COAT™ and managed care business. Not all of this was achieved without some headwinds, as some customers in the USA reacted to the RSS launch in a negative fashion, believing it was a competitive move against their dental practice. This of course is not our intent. We believe that most of our dental customers get the vast majority of their business via traditional physician referral routes, and indeed this is an additional and complimentary channel, which should accelerate the overall adoption of oral therapy.

However, we did experience some growth impact during the 2nd and 3rd quarters in the USA, which diluted our overall growth for the year. Nonetheless we were able to still post strong annual results showing 12% revenue growth, which on a comparable basis would have been closer to 15%, due to a strengthening Australian Dollar against the US dollar. Our unit devices sales grew globally by 15% year on year, with growth of 21% in Europe, a 15% growth in North America and flat sales in APAC.

Global unit sales growth




Global revenue growth




SOMNOMED LIMITED CEO'S REPORT (CONTINUED)

We also posted a strong improvement in the profitability of our SomnoMed Core business, showing 60% improvement in EBITDA due to margin improvements and leveraging previous investments in sales and marketing. Overall, we posted a negative EBITDA of \$1.7m, due to a \$4.1m loss in our newly formed RSS business.

Group Gross Margin %




EBITDA*



* EBITDA as adjusted does not include share and option expense, gain/(loss) on contingent consideration payable and impairment of goodwill

Total revenue split by region



■ North America ■ Europe ■ APAC

The split of revenues between our three global regions did not change significantly from the previous year, however, as a result of the expansion of our business in the USA through the addition of RSS, the revenue share of North America will grow substantially over the next three years.

SOMNOMED LIMITED

CEO'S REPORT (CONTINUED)



Renew Sleep Solutions successful launch

Significant effort was expended in launching our RSS initiative in the USA. This business which involves attracting potential patients via direct to consumer marketing, and then providing them with a turnkey service, consisting of sleep diagnosis, insurance reimbursement applications and processing, fitting sleep apnea MAS devices and patient follow up, and great patient experience was successfully launched. This involved the establishment of our central management, central marketing, re-imburement and care co-ordination capabilities in Dallas, as well as the opening of the first RSS centres in Tulsa, Oklahoma City, Kansas City, St Louis, Philadelphia, Phoenix and Milwaukee. Results from the first 3 centres, which have been open for more than 4 months during the financial year 2016/17, have provided very encouraging results and have shown positive patient flow and contribution margin, giving us confidence that what we have built will provide us with significant growth in 2017/18.

North American core business had to navigate reactions to the launch of RSS

Whilst we were very pleased with the launch of RSS in the USA, it provided some headwinds for our USA SomnoMed core business. The concept of RSS is creating an additional channel for the treatment of OSA patients and will accelerate the adoption of COAT™. Using consumer advertising it aims to raise the awareness of OSA and COAT™ as a comfortable and effective alternative treatment. RSS campaigns are most likely not only to attract patients, who otherwise would not be treated, but also raise the water level for all traditional treatment channels. However, not all dentists saw it this way, and following the launch of RSS we received some angry messages from some of our customers. This affected the growth in our traditional SomnoMed channel, especially during Q2 and Q3. By Q4 most of these issues had been successfully navigated and we finished the year with strong growth in Q4 (+24% unit growth), which lifted the North American unit growth for the year to 14.9%.

Europe showing an excellent 20% unit growth

Results in Europe were very satisfying, with all elements of our business performing to or above expectations. Our more developed businesses in countries, such as Sweden and the Netherlands, continued to show strong growth because of the growing OSA market, as well as taking share from Continuous Positive Airway Pressure ("CPAP").

In our emerging markets such as Norway, Belgium and France we are very encouraged by favourable changes in the way COAT™ therapy is supported by more favourable re-imburement and positive clinical guidelines for the use of COAT™. These countries are beginning to show accelerated growth as these favourable changes start to take effect. To complement the positive changes in those countries, new clinical guidelines issued during the last financial year in Germany and Finland are now also more favourable to COAT™. This is starting to show positive effects on the market in these countries, even if re-imburement is not yet available in the same systematic fashion as in Sweden and Holland.

Other business development efforts in the UK, Spain, Italy, Denmark and Switzerland promise to provide continuous growth in the region for many years to come.

APAC – COAT™ demand limited due to lack of reimbursement

The 2016/17 financial year was stagnate for the APAC region, which is predominantly Australia. Sales were essentially flat, although the region continued to be profitable. The primary challenge in all countries in this region is the lack of re-imburement, meaning the region essentially consists of private pay markets. Whilst we believe insurers in the APAC region will eventually recognise the advantages of COAT™ and move to some form of reimbursement for the treatment, it is not likely to occur in the near future.

SOMNOMED LIMITED

CEO'S REPORT (CONTINUED)

Scaling the business and developing a robust Product Development pipeline

While our overall business, sales and marketing as well as business development efforts were having full effect during the year it is important to ensure that we have an innovative product development pipeline, as well as scalable and efficient operations.

Towards the later part of the financial year we expanded our Global Operations and Product Development departments by clearly separating the functions into two departments. This involved the appointment of a Head for Global Operations, based in the US who has direct responsibilities for our production plant and all our service hubs around the world.

On the product development side we were able to launch our new patented temporary transition device called SomnoDent[®] Alpha. The purpose of this device is to demonstrate to patients or providers who require some re-assurance that a long term custom made device will be sufficiently effective given their individual condition. Whilst it is our belief that in the vast majority of mild and moderate patients this should not be necessary, an Alpha test could be beneficial to the patient and the sleep practitioner prior to the treatment of severe patients.

On the operational side, we were happy to introduce 100% digital scanning of dental impressions in our hubs, which has helped us to improve our gross margin to 70% during the financial year 2016/17. We are now encouraging and are taking Intra-oral scans directly from dentists from several different intra-oral scanners. This provides a better patient experience, speeds up the process, improves the quality of impressions, as well as reducing costs.

We are also looking at all of our operational processes and systems and ensuring that we combine the best of lean manufacturing process with appropriate dental domain expertise. We are in the process of developing new operations processes and are introducing new systems as well as acquiring new operational talents, to ensure that our operations scale effectively and efficiently and to enable us to successfully digest the significant volume growth anticipated in the financial year 2017/18 and beyond.

The year ahead

We are very optimistic about our business and its growth prospects in 2017/18. The continuing growth and incidence rate of OSA in all the countries in which we operate, the growing need for an effective alternative to CPAP and the accelerated adoption of COAT[™] as a therapy are all good fundamental trends for the future growth of our business. Our ongoing and strong growth in Europe and confidence that we can sustain positive growth in our core North American SomnoMed business provide a strong platform for growth for SomnoMed. In addition to this we will expect to get strong growth from the RSS centres that were opened in 2016/17, as well as those that will be opened in the first half of 2017/18. We expect to open 10-12 new centres in 2017/18, a pace similar to that achieved in the financial year 2016/17. As a result, the combined revenues are expected to grow by 50% to 60% to \$75 to \$80 million in 2017/18.

Our operational improvements in the SomnoMed core business, as well as the effect of efficient scaling, will mean that our EBITDA for this part of our business should again grow significantly in 2017/18. The continuing investment in opening new RSS treatment centres across the USA will require additional investments, partly offset by earnings of outlets operating for more than six months. However, we still expect RSS to produce a negative EBITDA in the financial year 2017/18, albeit much reduced from that of the financial year 2016/17. After allowing for the negative contribution from RSS we still expect to double the SomnoMed group EBITDA to around \$5 million in 2017/18.

SOMNOMED LIMITED
CEO'S REPORT (CONTINUED)

The year ahead (continued)

Our guidance for 2017/18 is shown below:

	2017/18	2016/17
Revenues	\$75m-\$80m*	\$49.3m
EBITDA**	\$5m*	(\$1.7m)

*Based on average exchange rate 2017/18, A\$/US\$: 0.77, A\$/EURO: 0.68

**EBITDA as adjusted does not include share and option expense, gain/(loss) on contingent consideration payable and impairment of goodwill

Our guidance for the financial year 2017/18 reflects the growth on our core business and the impact of our RSS concept. Given the increasing acceptance of COAT™ in many of our markets and the higher patient flow generated through the RSS concept in the USA, I believe high growth is likely to continue for some time. SomnoMed has a very strong future ahead and it is a privilege to lead a company that helps people to sleep and perform better, increases their life expectancy and allow them to enjoy a happier and healthier life.

I would like to extend my thanks to our management and employees throughout the world, the physicians and dentists who support this therapy, and of course to the support of our shareholders.

Yours sincerely,



Mr Derek Smith
Global Chief Executive Officer

SOMNOMED LIMITED
ACN 003255221
DIRECTORS' REPORT

The directors present their report, together with the financial statements, on the Consolidated Entity (referred to hereafter as the 'Consolidated Entity') consisting of SomnoMed Limited (referred to hereafter as the 'company' or 'parent entity') and the entities it controlled at the end of, or during, the year ended 30 June 2017.

Directors

The names of directors in office at any time during or since the end of the year are:

Peter Neustadt

Robert Scherini

Lee Ausburn

Directors have been in office since the start of the financial year to the date of this report, unless otherwise stated.

Principal Activity

The principal activity of the Consolidated Entity during the financial year was the commercialisation of the SomnoDent[®] MAS and other oral devices for sleep related disorders in Australia and overseas.

There were no significant changes in the nature of the Consolidated Entity's principal activities during the financial year.

Operating Results

The loss of the Consolidated Entity amounted to \$4,163,331 (2016: a profit of \$67,185). A more detailed review of the operations is contained on pages 2 to 6 of the Annual Report, which accompanies this Directors' Report.

Dividends Paid or Recommended

There are no dividends paid, declared or recommended for the year ended 30 June 2017 (2016: Nil).

Significant Changes in State of Affairs

Other than as stated in the accompanying CEO's Report and financial report, there were no significant changes in the state of affairs of the Company during the reporting year.

After Balance Date Events

The directors have not become aware of any matter or circumstance that has arisen since the end of the year to the date of this report that has significantly affected or may affect:

- (i) The operations of the Company and the entities that it controls
- (ii) The results of those operations
- (iii) The state of affairs of the Company in subsequent years.

Future Developments

The Company will continue to produce and sell devices for the oral treatment of sleep related disorders in Australia and overseas.

SOMNOMED LIMITED

DIRECTORS' REPORT (CONTINUED)

Directors

Peter Neustadt

Non-Executive Chairman, Member of the Audit Committee

Dr. Peter Neustadt, born in Germany, studied in Switzerland at St.Gall Graduate School for Business & Economics, where he earned a Master in Economics (lic.oec.HSG) and Doctorate in Business Administration (Dr.oec). He worked for McKinsey & Company based in Switzerland and in Mexico.

Dr Neustadt moved to Australia and joined Kerry Packer in 1980 as a member of the executive board of Consolidated Press Holdings. He was Executive Chairman and principal shareholder in diverse media group Communications & Entertainment Limited until 1987. He founded and managed resort and property group Cypress Lakes Group Limited and The Golden Door group of companies until the end of 2005. Dr Neustadt also served on the board of Channel Ten, Advance Bank, Trafalgar Properties Limited and Manboom Pty Ltd.

From February 2010 to August 2014 he chaired Australian financial services company and mortgage aggregator Vow Financial and negotiated the takeover of the company by Yellow Brick Road Limited. The transaction completed at the end of August 2014. He also serves as director on the board of private companies in Australia and in Europe.

Robert Scherini

Non-Executive Director, Chairman of the Audit Committee

Rob is a past Managing Director for Johnson & Johnson Medical Australia/NZ and has held senior management positions both locally and internationally. He was posted for a number of years in J&J's European headquarters in Brussels before returning to Australia where he was directly responsible for J&J's medical device business in Australia and New Zealand as well as responsibilities across the APAC region. He has a strong track record of growing businesses and brings to the Board a wealth of experience in Sales & Marketing, Business Development, Finance, Operations and Supply, Legal, Human Resources and Information Technology.

Rob has a bachelor's degree in Business and is a Certified Practising Accountant (CPA). He was a Member of the Board of the Medical Technology Association of Australia (MTAA) for nine years. He has been a strong advocate of Human Resources Strategy and was recognised as Best HR Champion at the 2004 Australian HR Awards. In 2007 was awarded a Rotary International Fellowship for his assistance to the community.

More recently Rob has devoted his time to consulting and mentoring. He is a senior advisor for a healthcare consultancy focused on Asia Pacific and a member of the Board of a large privately owned medical device company.

Lee Ausburn

Non-Executive Director, M.Pharm., B.Pharm., Dip.Hosp.Pharm. (University of Sydney), FAICD

Lee has had a long career in the health industry, beginning as a pharmacist before joining Merck and Co. Inc., a global pharmaceutical company. She progressed through a range of roles, beginning in marketing in Australia and was ultimately Vice President, Asia Merck & Co. Inc. responsible for the general management of Merck organisations and their products across Asia. During this time, Lee successfully built businesses in a number of countries, often from the very beginning, planned and launched new products, liaised with regulatory authorities and government agencies and was responsible for the management teams building Merck's business in that part of the world. After leaving Merck in 2008, she has taken on a number of non-executive director roles.

She is a non-executive director of Australian Pharmaceutical Industries (API) Ltd, which distributes pharmaceuticals to pharmacies across Australia. API also has retail pharmacy operations through Priceline stores. She is also a non-executive director of nib holdings ltd, a health insurer.

Lee is currently President of the Pharmacy Faculty Foundation, University of Sydney.

Chief Executive Officer

Derek Smith B.Sc., Biochemistry

Derek held senior positions with Respiroics, Inc. since 2005 and prior to his appointment as Chief Executive Officer of the Company in September 2016. He had an outstanding career over the years in sales and marketing of various US and international healthcare companies, which included E Merck, Datex Ohmeda and McKesson. In 2005 Derek accepted the appointment as President of Respiroics Hospital Group, being part of the top management team of the leading US CPAP maker. Following the takeover of Respiroics in 2008 by global Philips corporation, Derek held positions as Senior Vice President of Respiratory and Perinatal Care for Philips Healthcare, as Senior Vice President of Therapeutic Care and finally as CEO Hospital to Home Business division at Philips Healthcare.

Company Secretary

Terence Flitcroft B Comm CA SF FIN

Terence has been Company Secretary since 1995.

Terence is a Chartered Accountant with broad commercial and financial experience and has acted as director and company secretary for a number of private and public companies.

SOMNOMED LIMITED DIRECTORS' REPORT (CONTINUED)

Board Member's Directorships

Listed below are details of other listed public company directorships held by Board Members over the last three years.

Director	Directorship of	Date Appointed	Date Resigned
Peter Neustadt	No other listed public company directorship	-	-
Robert Scherini	No other listed public company directorship	-	-
Lee Ausburn	Australian Pharmaceutical Industries Ltd	7 October 2008	Current
	nib holdings ltd	13 November 2013	Current

Directors' Interests in Securities

As at the date of this report, details of Directors who hold shares or options in the Company for their own benefit or who have an interest in holdings through a third party are detailed below.

Director	Shares	Options over Ordinary Shares
Peter Neustadt *	2,806,705	675,000
Robert Scherini *	86,400	-
Lee Ausburn *	133,919	-

* Held by the Director or entities associated with the Director and in which the Director has a financial interest.

Meetings of Directors

The number of meetings of the Company's Board of Directors and each board committee held during the year to 30 June 2017 and the number of meetings attended by each director were:

	DIRECTORS' MEETINGS		COMMITTEE MEETINGS			
			AUDIT COMMITTEE		REMUNERATION COMMITTEE	
	Number eligible to attend	Number Attended	Number eligible to attend	Number Attended	Number eligible to attend	Number Attended
Peter Neustadt	12	12	2	2	1	1
Robert Scherini	12	12	2	2	1	1
Lee Ausburn	12	12	-	-	1	1

SOMNOMED LIMITED DIRECTORS' REPORT (CONTINUED)

Indemnifying Directors or Officers

Each Director has entered into a Deed with the Company under which the Director is given access to documentation and in addition is:

- indemnified by the Company to the full extent permitted by law against all liabilities sustained or incurred through acting as a Director (under the Corporations Act the indemnity does not extend to a liability owed to the Company or its related bodies corporate, or which arises out of conduct involving a lack of good faith, or is for a pecuniary penalty order under section 1317G of the Corporations Act or a compensation order under section 1317H of the Corporations Act);
- indemnified by the Company to the full extent permitted by law against legal costs and expenses incurred in defending an action for a liability incurred as an officer of the Company (under the Corporations Act the indemnity does not extend to costs incurred in circumstances where the Director is found to have a liability for which the Director cannot be indemnified, or costs of defending or resisting criminal proceedings in which the Director is found guilty or defending proceedings brought by ASIC or a liquidator for a court order where the court holds that the grounds for making the order are established, or costs of proceedings seeking relief for the Director under the Corporations Act where the court denies relief);
- entitled to a loan to meet the costs of defending or responding to any such claim or proceeding; and
- entitled to have the Company maintain and pay premiums in respect of directors' and officers' insurance. Premiums paid in respect of this insurance were \$46,454.

Corporate Governance

In recognising the need for the highest standards of corporate behaviour and accountability, the directors of SomnoMed Limited support and have adhered to key principles of corporate governance.

Please refer to the Corporate Governance Statement of SomnoMed Limited on our website for more information <http://somnomed.com/au/about-us/investor-centre/corporate-governance>.

Environmental regulations

The Company's operations are not materially affected by environmental regulations.

Proceedings on Behalf of Company

No person has applied for leave of Court to bring proceedings on behalf of the Company or intervene in any proceedings to which the Company is a party for the purpose of taking responsibility on behalf of the Company for all or any part of those proceedings.

The Company was not a party to any such proceedings during the year.

SOMNOMED LIMITED DIRECTORS' REPORT (CONTINUED)

Options

At the date of this report the unissued ordinary shares of SomnoMed Limited under option are as follows:

Grant Dates	Date of Expiry	Exercise Price	Number under Option
2 December 2014	31 October 2017	\$2.35	250,000
25 November 2015	31 October 2018	\$2.64	250,000
1 September 2016	31 August 2019	\$3.39	200,000
7 October 2016	30 September 2021	\$3.44	300,000
24 November 2016	31 October 2019	\$3.78	175,000
			1,175,000

In addition to the above 1,175,000 options, a total of 3,628,834 shares issued by the Company pursuant to the Company's Executive Share and Option Plan have been treated as share based payments (exercise price equals issue price) in the accounts accompanying this Directors' Report, in accordance with the Company's accounting policies and Australian Accounting Standards (refer Note 15 to the accompanying accounts).

No options were granted over unissued shares during or since the end of the financial year by the Company to directors or any of the specified officers as part of their remuneration, other than:

Option holder	Exercise price	Options
P Neustadt Holdings Pty Limited*	\$3.78	175,000
Derek Smith**	\$3.39	200,000
Derek Smith	\$3.44	300,000
		675,000

* P Neustadt Holdings Pty Limited is a company associated with Dr Peter Neustadt.

** Mr Smith was appointed Chief Executive Officer effective 1st September 2016 and the parcel of 200,000 options was advised in previous year's Directors' Report

A total of 600,000 options have been exercised since the end of the last financial year.

No options expired or lapsed since the end of the previous financial year, which were not reported in the previous year's Directors' Report.

No person entitled to exercise the option had or has any right by virtue of the option to participate in any share issue of any other body corporate.

SOMNOMED LIMITED DIRECTORS' REPORT (CONTINUED)

REMUNERATION REPORT

This report details the nature and amount of remuneration for each director of SomnoMed Limited and for the executives receiving the highest remuneration.

Remuneration Policy

The remuneration policy of SomnoMed Limited has been designed to align director and executive objectives with shareholder and business objectives by providing a fixed remuneration component and offering specific long-term incentives based on key performance areas affecting the Consolidated Entity's financial results. The board of SomnoMed Limited believes the remuneration policy to be appropriate and effective in its ability to attract and retain the best executives and directors to run and manage the Consolidated Entity, as well as create goal congruence between directors, executives and shareholders.

The following table shows the gross revenue and results for the last five years for the listed entity, as well as the share price at the end of the respective financial years.

	2013	2014	2015	2016	2017
Revenue	\$18,581,690	\$30,274,596	\$34,437,903	\$44,084,153	\$49,326,974
Net profit/(loss)	\$704,675	\$214,956	\$533,761	\$67,185	(\$4,163,331)
Share price at year end	\$0.91	\$1.46	\$2.65	\$3.59	\$3.06
Earnings per share (cents)	1.39	0.95	1.26	0.34	(6.23)

The board's policy for determining the nature and amount of remuneration for board members and senior executives of the Consolidated Entity is as follows:

The remuneration policy, setting the terms and conditions for the executive directors and other senior executives, was developed by the remuneration committee, which currently is the entire board. All executives receive a total remuneration package, which may include a base salary (commensurate with their expertise and experience), superannuation, fringe benefits, options and performance incentives. The remuneration committee reviews executive packages annually by reference to the Consolidated Entity's performance and executive performance.

The performance of executives is measured with each executive and is based predominantly on the forecast growth of the Company's financial performance, the achievement of the annual budget for their respective areas and shareholders' value. All bonuses and incentives are linked to predetermined performance criteria. Changes must be justified by reference to measurable performance criteria. The policy is designed to attract the highest calibre of executives and reward them for performance that results in the achievement of annual targets and building long-term growth in shareholder wealth.

Executives are also entitled to participate in the employee option arrangements.

Senior executives in Australia receive a superannuation guarantee contribution required by the government, which is currently 9.5%, and do not receive any other retirement benefits. Some individuals, however, have chosen to sacrifice part of their salary to increase payments towards superannuation.

All remuneration paid to directors and executives is valued at the cost to the Company and expensed. Options are valued using the Black Scholes methodology.

The board policy is to remunerate non-executive directors at market rates for comparable companies for time, commitment and responsibilities. The remuneration committee determines payments to the non-executive directors and reviews their remuneration annually, based on market practice, duties and accountability. Fees for non-executive directors are not linked to the performance of the Consolidated Entity. However, to align directors' interests with shareholder interests, the directors may hold options in the Company.

Performance Based Remuneration

As part of senior executives' remuneration packages there is a performance-based component, consisting of key performance indicators (KPIs). The intention of this program is to facilitate goal congruence between executives with that of the business and shareholders. The KPIs are set annually, with a certain level of consultation with executives. The measures are specifically tailored to the areas each executive is involved in and has a level of control over but are also linked to the overall results achieved by the Company. KPIs target areas are typically linked to areas and results which will improve the performance of the Company, covering financial and non-financial as well as short- and long-term goals. The level set for each KPI is based on budgeted figures for the group.

SOMNOMED LIMITED DIRECTORS' REPORT (CONTINUED)

Performance Based Remuneration (continued)

Performance in relation to the KPIs is assessed annually, with bonuses being awarded depending on the KPIs achieved. Following the assessment, the KPIs are reviewed by the Remuneration Committee in light of the desired and actual outcomes, and their efficiency is assessed in relation to the group's goals and shareholder wealth, before the KPIs are set for the following year.

KPIs relating to short-term incentives (STIs) relate to performance benchmarks against measured targets designed to reward superior performance and are only rewarded when performance hurdles are met. In most cases this is linked to the achievement of the annual budget for a certain region, country or functional area. However, the benchmarks for STI hurdles might vary from year to year. The current year performance hurdles include the measurement of performance against financial budgets, successful opening of RSS outlets and a number of other items relevant to the particular employee's role.

The major long-term incentives (LTIs) for employees are related to equity and options granted to senior executives pursuant to the Company's Executive Share and Option Plan. Employees are invited to participate in this plan on an annual basis. The Remuneration Committee sets the overall quantum of shares to be issued and approves the allocation to individual on the basis of recommendations it receives from the CEO and the heads of regional and global departments. The performance of the executive in the financial year gone by is an important factor which is taken into consideration in determining the allocation to each employee, however, the main criteria are the importance of the role an individual plays and his or her value to the future development of our company. Vesting conditions apply to units issued under the Company's Employee Share Trust and units vest progressively over a number of years. Units issued in the 2016/17 financial year vest over a period of four years – half at the third anniversary from the date of issue and the other half on the fourth anniversary. This provides employees with a long-term incentive to continue to add value to the Company's operations and remain employed with SomnoMed.

In determining whether or not a KPI has been achieved, SomnoMed Limited bases the assessment on audited figures where appropriate.

Company Performance, Shareholder Wealth and Directors' and Executives' Remuneration

The remuneration policy has been tailored to increase goal congruence between shareholders and directors and executives. There have been two methods applied in achieving this aim, the first being a performance based bonus based on key performance indicators, and the second being the issue of options to directors and executives to encourage the alignment of personal and shareholder interests. The Company believes this policy is effective in increasing shareholder wealth over the medium term.

The board will review its remuneration policy annually to ensure it is effective.

Performance Income as a proportion of Total Remuneration

Senior executives are paid performance based bonuses based on a proportion of their total remuneration package. The remuneration committee has set these bonuses to encourage achievement of specific goals that have been given a high level of importance in relation to the future growth and financial performance of the Consolidated Entity. The remuneration committee will review the performance bonuses to gauge their effectiveness against achievement of the set goals, and adjust future years' incentives as they see fit, to ensure use of the most cost effective and efficient methods.

Except for the Chairman, who acted as an Executive Chairman and CEO until September 2016, all senior executives' remuneration for the year ended 30 June 2017 had a fixed component and a variable component of their overall remuneration, with the variable part of their remuneration paid subject to a performance condition.

Employment Contracts of Directors and Senior Executives

The employment conditions of specified executives are formalised in contracts of employment or its wholly owned subsidiary, with the exception of the Chairman, who acted as an Executive Chairman and CEO until September 2016. All executives other than the Chairman during his time for which he acted as Executive Chairman and CEO are permanent employees of SomnoMed. No contract is for a fixed term. Each contract states it can be terminated by the Company by giving up to six months' notice and by paying a redundancy of between three to six months.

SOMNOMED LIMITED DIRECTORS' REPORT (CONTINUED)

Options issued as part of remuneration for the year ended 30 June 2017

During the year, options were issued to the Chairman and CEO as part of their remuneration. The options are not issued based on performance criteria, but are from time to time issued to directors and executives of SomnoMed Limited and its subsidiaries to increase long term goal congruence between executives, directors and shareholders.

Company Directors/ Executives	Granted Number	Grant Date	Value per Option at Grant Date	Exercise Price	Earliest Exercise Date	Last Exercise Date
P Neustadt Holdings Pty Limited *	175,000	24 November 2016	\$1.105	\$3.78	30 June 2017	31 October 2019
Derek Smith	200,000	1 September 2016	\$1.194	\$3.39	1 September 2016	30 August 2019
Derek Smith	300,000	7 October 2016	\$1.493	\$3.44	1 October 2019	30 September 2021

* Issued to P Neustadt Holdings Pty Limited is a company associated with Dr Peter Neustadt.

Directors' remuneration

The following table discloses the remuneration of Directors of the Company for the year ended 30 June 2017, as specified for disclosure by AASB 124. The information contained in this table is audited.

Director	Short-term Benefits		Post-Employment Benefits	Long-term Benefits		Total \$
	Salary & Fees \$	Other \$	Superannuation \$	Termination Benefits \$	Equity Settled Share Based Payment	
Peter Neustadt (1)						
- 2016	550,000	-	-	-	131,712	681,712
- 2017	238,900	-	-	-	187,792	426,692
Robert Scherini						
- 2016	58,625	-	-	-	-	58,625
- 2017	61,800	-	-	-	-	61,800
Lee Ausburn (2)						
- 2016	58,625	-	-	-	-	58,625
- 2017	61,800	-	-	-	-	61,800
TOTAL 2016	667,250	-	-	-	131,712	798,962
TOTAL 2017	326,500	-	-	-	187,792	550,292

(1) Dr Neustadt is a director of Belgove Pty Limited, which received consultancy fees during this and the previous year.

(2) Ms Ausburn is a director of Leedoc Pty Limited, which received consultancy fees during this and the previous year.

SOMNOMED LIMITED DIRECTORS' REPORT (CONTINUED)

Shareholdings

Number of shares held by the Directors and Key Management Personnel, including shares held by associated entities.

	Balance 1.7.16 ⁽⁴⁾	Issued	Sold	Exercise of Options	Balance 30.6.17
Peter Neustadt	4,106,705	-	(1,500,000)	200,000	2,806,705
Lee Ausburn	133,919	-	-	-	133,919
Robert Scherini	86,400	-	-	-	86,400
Derek Smith	-	-	-	-	-
Jim Evanger	-	-	-	-	-
Kien Nguyen ⁽¹⁾	1,035,000	90,000	(200,000)	-	925,000
Neil Verdal-Austin ⁽²⁾	1,170,000	100,000	(450,000)	-	820,000
Martin Weiland ⁽³⁾	300,000	80,000	(50,000)	-	330,000
	<u>6,832,024</u>	<u>270,000</u>	<u>(2,200,000)</u>	<u>200,000</u>	<u>5,102,024</u>
Less shares issued under the Employee Share Trust Plan ^{(1), (2) & (3)}	(2,345,000)	(270,000)	-	-	(2,615,000)
	<u>4,497,024</u>	<u>-</u>	<u>(2,200,000)</u>	<u>200,000</u>	<u>2,487,024</u>

- (1) 90,000 (2016: 335,000) shares issued by the Company utilising funds advanced by the Company to purchase these shares pursuant to the Company's Executive Share and Option Plan (refer Note 15). These shares are treated as options in these accounts in accordance with the Company's accounting policies and Australian Accounting Standards.
- (2) 100,000 (2016: 135,000) shares issued by the Company utilising funds advanced by the Company to purchase these shares pursuant to the Company's Executive Share and Option Plan (refer Note 15). These shares are treated as options in these accounts in accordance with the Company's accounting policies and Australian Accounting Standards.
- (3) 80,000 (2016: 80,000) shares issued by the Company utilising funds advanced by the Company to purchase these shares pursuant to the Company's Executive Share and Option Plan (refer Note 15). These shares are treated as options in these accounts in accordance with the Company's accounting policies and Australian Accounting Standards.
- (4) Mr Chris Bedford was a Key Management Person at 30 June 2016 and held 300,000 issued shares at that date, which were treated as options in those accounts. During the year ended 30th June 2017, he was not considered a Key Management Person.

SOMNOMED LIMITED DIRECTORS' REPORT (CONTINUED)

Options and Rights Holdings

Number of options held by the Directors and Key Management Personnel, including options held by associated entities

	Balance 1.7.16 ⁽⁴⁾	Granted as Remuneration/ on Employment Commencement	Exercised or Lapsed/ Expired	Balance 30.6.17	Total Vested 30.6.17	Total Exercisable	Total Un-exercisable
Peter Neustadt ⁽¹⁾	700,000	175,000	(200,000)	675,000	675,000	675,000	-
Robert Scherini	-	-	-	-	-	-	-
Lee Ausburn	-	-	-	-	-	-	-
Derek Smith ⁽²⁾	-	500,000	-	500,000	200,000	200,000	300,000
Jim Evanger	-	-	-	-	-	-	-
Neil Verdall-Austin	-	-	-	-	-	-	-
Kien Nguyen	-	-	-	-	-	-	-
Martin Weiland	-	-	-	-	-	-	-
Total	700,000	675,000	(200,000)	1,175,000	875,000	875,000	300,000
Issued shares treated as options in these accounts ⁽³⁾ (refer table above and Note 15)							
Kien Nguyen	1,035,000	90,000	(200,000)	925,000	100,000	100,000	825,000
Neil Verdall-Austin	1,010,000	100,000	(450,000)	660,000	175,000	175,000	485,000
Martin Weiland	300,000	80,000	(50,000)	330,000	25,000	25,000	305,000
Total	3,045,000	945,000	(900,000)	3,090,000	1,175,000	1,175,000	1,915,000

- (1) Held by Belgrove Pty Limited or its nominee, a company associated with Dr Peter Neustadt. 175,000 options were issued to P Neustadt Holdings Pty Ltd on 24 November 2016, with an exercise price of \$3.78 per share, each entitling the option holder to be issued with one new ordinary share. The options could not be exercised before 30 June 2017 and expire on 31 October 2019. Fair value of these options calculated by using a Black and Scholes option pricing model was \$1.105 per option.
- (2) Mr Derek Smith commenced employment on 1st September 2016. On commencement of his employment, Mr Smith was issued 200,000 options with an exercise price of \$3.39 per share and on 7th October 2016 he was issued with 300,000 options with an exercise price of \$3.44 per share. Fair value of these options calculated by using a Black and Scholes option pricing model was \$1.194 and \$1.493 per option respectively.
- (3) The options were issued by the Company pursuant to the Company's Executive Share and Option Plan and have been treated as share based payments (exercise price equals issue price) in the accounts accompanying this Directors' Report, in accordance with the Company's accounting policies and Australian Accounting Standards. These options were issued on 7 October 2016 at an exercise price of \$3.44 per share. These options expire on 31 October 2021 and are exercisable prior to that time, subject to vesting conditions being satisfied. Fair value of these options calculated by using a Black and Scholes option pricing model was \$1.495 per option.
- (4) Mr Chris Bedford was a Key Management Person at 30 June 2016 and held 300,000 issued shares at that date, which were treated as options in those accounts. During the year ended 30th June 2017, he was not considered a Key Management Person.

Loans to key management personnel

Details of loans to key management personnel are reflected in Note 26(d).

SOMNOMED LIMITED DIRECTORS' REPORT (CONTINUED)

Executives' remuneration

The following table discloses the remuneration of the specified executives of the company and the Consolidated Entity for the year ended 30 June 2017, as specified for disclosure by AASB 124. The information in this table is audited.

Executive	Salary & Fees	Short-term Benefits		Post- Employment Benefits	Long-term Benefits	Share-based Payment (1)	Termination Benefits	Total
		Bonuses	Other	Superannuation	Long service leave			
Derek Smith ⁽²⁾								
- 2017	547,533	-	-	-	-	294,788	-	842,321
- 2016	-	-	-	-	-	-	-	-
Neil Verdal-Austin								
- 2017	366,000	33,333	-	34,770	12,789	101,794	-	548,686
- 2016	330,000	-	-	31,350	10,365	30,193	-	401,908
Jim Evanger ⁽³⁾								
- 2017	409,482	170,384	10,915	-	-	-	-	590,781
- 2016	-	-	-	-	-	-	-	-
Kien Nguyen								
- 2017	531,067	-	20,354	-	-	60,548	-	611,969
- 2016	506,502	-	35,025	-	-	45,082	-	586,609
Martin Weiland								
- 2017	334,308	58,140	20,185	-	-	68,770	-	481,402
- 2016	302,069	7,552	20,825	-	-	20,987	-	351,433
TOTAL 2017	2,188,391	261,856	51,453	34,770	12,789	525,900		3,075,159
TOTAL 2016	1,138,571	7,552	55,850	31,350	10,365	96,262	-	1,339,950

(1) The amounts disclosed are based on the assessed fair value at the date of grant using the Black-Scholes model and allocated to each reporting period evenly over the period from grant date to vesting date.

(2) Commenced employment 1st September 2016.

(3) Commenced employment 1st August 2016.

(4) Mr Chris Bedford was a Key Management Person (KMP) at 30 June 2016 and was not considered a KMP at 30 June 2017.

For the year ended 30 June 2017 the Company had five (2016 – four) persons employed who were deemed to be specified executives.

The key management personnel of the consolidated group comprise the directors and the specified executives.

Bonuses are awarded as part of the consolidated group's incentive scheme for the retention of key executives and are awarded as at year end. All bonuses have vested and the pre-requisites for the receipt of the award have been satisfied.

The terms and conditions relating to options granted as remuneration during the year to key management personnel are disclosed in Note 24.

SOMNOMED LIMITED DIRECTORS' REPORT (CONTINUED)

The proportion of remuneration linked to performance and the fixed proportion are as follows:

Name	Fixed remuneration		At risk – STI		At risk – LTI	
	2017	2016	2017	2016	2017	2016
<i>Non-Executive Directors:</i>						
Peter Neustadt*	56%	81%	0%	0%	44%	19%
Robert Scherini	100%	100%	0%	0%	0%	0%
Lee Ausburn	100%	100%	0%	0%	0%	0%
<i>Other Key Management Personnel:</i>						
Derek Smith**	48%	-	26%	-	26%	-
Neil Verdai-Austin	68%	76%	15%	18%	17%	6%
Jim Evanger***	68%	-	32%	-	0%	-
Kien Nguyen	71%	72%	21%	22%	8%	6%
Martin Weiland	71%	80%	15%	15%	14%	5%

* Dr Neustadt was an Executive Director until September 2016 and since that time he has been a Non-Executive Director.

** Commenced employment 1st September 2016.

*** Commenced employment 1st August 2016.

The proportion of the cash bonus paid/payable or forfeited is as follows:

Name	Cash bonus paid/payable		Cash bonus forfeited	
	2017	2016	2017	2016
<i>Non-Executive Directors:</i>				
Peter Neustadt*	-	-	-	-
Robert Scherini	-	-	-	-
Lee Ausburn	-	-	-	-
<i>Other Key Management Personnel:</i>				
Derek Smith**	0%	-	100%	-
Neil Verdai-Austin	37%	0%	63%	100%
Jim Evanger***	85%	-	15%	-
Kien Nguyen	0%	0%	100%	100%
Martin Weiland	80%	12%	20%	88%

* Dr Neustadt was an Executive Director until September 2016 and since that time he has been a Non-Executive Director.

** Commenced employment 1st September 2016.

*** Commenced employment 1st August 2016.

This concludes the Remuneration Report which has been audited.

SOMNOMED LIMITED DIRECTORS' REPORT (CONTINUED)

Other Information

Non-audit Services

The board of directors, in accordance with advice from the audit committee, is satisfied that the provision of non-audit services during the year is compatible with the general standard of independence for auditors imposed by the *Corporations Act 2001*. The directors are satisfied that the services disclosed below did not compromise the external auditor's independence for the following reasons:

- all non-audit services are reviewed and approved by the audit committee prior to commencement to ensure they do not adversely affect the integrity and objectivity of the auditor; and
- the nature of the services provided do not compromise the general principles relating to auditor independence in accordance with APES 110: Code of Ethics for Professional Accountants set by the Accounting Professional and Ethical Standards Board.

Fees of \$297,000 (2016: \$46,000) for tax services were paid/payable to the external auditors during the year ended 30th June 2017.

Auditor's Independence Declaration

The auditor's independence declaration for the year ended 30th June 2017 is set out on page 59 of this annual report.

Signed in accordance with a resolution of the Board of Directors pursuant to section 298(2)(a) of the *Corporations Act 2001*.



Peter Neustadt

Chairman

25th September 2017

SOMNOMED LIMITED
ACN 003255221
**CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER
COMPREHENSIVE INCOME
FOR THE YEAR ENDED 30 JUNE 2017**

	NOTE	2017 \$	2016 \$
Revenue from sale of goods and services, net of discounts	5	49,326,974	44,084,153
Cost of sales		(20,517,224)	(18,741,061)
Gross margin		28,809,750	25,343,092
Sales and marketing expenses		(13,698,398)	(11,942,634)
Administrative expenses		(12,678,003)	(8,411,251)
Operating profit before corporate, research and business development expenses, other items of revenue and expenses and income tax		2,433,349	4,989,207
Corporate, research and business development expenses		(4,130,384)	(3,514,198)
Interest income	5	124,236	55,935
Net fair value (loss)/gain on contingent consideration payable	28	(32,551)	436,508
Share based payments	24c	(805,502)	(337,397)
Depreciation and amortisation		(1,232,311)	(1,020,054)
Impairment of goodwill		(40,000)	-
Impairment of capitalised development costs		-	(49,843)
Interest expense		(20,422)	(10,723)
Loss on disposal of fixed assets		(6,025)	-
Unrealised foreign exchange loss		(54,386)	(58,663)
(Loss)/profit before income tax	6	(3,763,996)	490,772
Income tax expense attributable to operating profit	7	(399,335)	(423,587)
(Loss)/profit after income tax for the year		(4,163,331)	67,185
Other comprehensive income			
<i>Items that may be reclassified subsequently to profit or loss</i>			
Foreign exchange translation difference for foreign operations		(761,137)	295,748
Other comprehensive income for the year, net of tax		(761,137)	295,748
Total comprehensive income for the year attributable to the owners of SomnoMed Limited		(4,924,468)	362,933
 (Loss)/profit for the period is attributable to:			
Owners of SomnoMed Limited		(3,343,878)	165,005
Non-controlling interest		(819,453)	(97,820)
		(4,163,331)	67,185
 Total comprehensive income for the year attributable to:			
Owners of SomnoMed Limited		(4,105,015)	460,753
Non-controlling interest		(819,453)	(97,820)
		(4,924,468)	362,933
Basic earnings per share (cents per share)	22	(6.23)	0.34
Diluted earnings per share (cents per share)	22	(6.23)	0.32

The above statement should be read in conjunction with the consolidated notes.

SOMNOMED LIMITED
ACN 003255221
CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS AT 30 JUNE 2017

	NOTE	2017	2016
		\$	\$
ASSETS			
Current Assets			
Cash and cash equivalents	8	14,210,321	17,632,252
Trade and other receivables	9	10,196,708	7,847,165
Inventories	10	1,947,565	1,690,632
Total Current Assets		26,354,594	27,170,049
Non-Current Assets			
Trade and other receivables		264,738	-
Property, plant and equipment	11	4,491,423	3,572,965
Intangible assets	12	6,632,530	6,621,921
Deferred tax asset	7c	3,468,762	3,062,237
Total Non-Current Assets		14,857,453	13,257,123
Total Assets		41,212,047	40,427,172
LIABILITIES			
Current Liabilities			
Trade and other payables	13	8,005,382	6,085,053
Provisions	14	1,547,355	936,820
Current tax liability		449,665	375,759
Contingent consideration payable	29	-	179,695
Total Current Liabilities		10,002,402	7,577,327
Non-Current Liabilities			
Provisions	14	254,839	161,217
Total Non-Current Liabilities		254,839	161,217
Total Liabilities		10,257,241	7,738,544
Net Assets		30,954,806	32,688,628
EQUITY			
Issued capital	15	46,937,360	44,552,216
Reserves	16	4,415,906	4,371,541
Accumulated losses		(19,139,530)	(15,795,652)
Equity attributable to owners of SomnoMed Limited		32,213,736	33,128,105
Non-controlling interests		(1,258,930)	(439,477)
Total Equity		30,954,806	32,688,628

The above statement should be read in conjunction with the consolidated notes.

SOMNOMED LIMITED
ACN 003255221
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 30 JUNE 2017

	Issued Capital	Reserves	Accumulated Losses	Owners of parent	Non- controlling interest	Total
	\$	\$	\$	\$	\$	\$
Balance at 1 July 2015	33,705,941	3,566,396	(15,932,383)	21,339,954	168,028	21,507,982
Revaluation of employee retirement benefit	-	-	(28,274)	(28,274)	-	(28,274)
Profit after income tax expense for the year	-	-	165,005	165,005	(97,820)	67,185
Other comprehensive income for the year, net of tax	-	295,748	-	295,748	-	295,748
Total comprehensive income for the year	-	295,748	165,005	460,753	(97,820)	362,933
<i>Transactions with owners in their capacity as owners:</i>						
Shares issued during the period	11,265,712	-	-	11,265,712	-	11,265,712
Share issuance costs	(419,437)	-	-	(419,437)	-	(419,437)
Share option reserve on recognition of remuneration options	-	509,397	-	509,397	-	509,397
Acquisition	-	-	-	-	(509,685)	(509,685)
Balance at 30 June 2016	44,552,216	4,371,541	(15,795,652)	33,128,105	(439,477)	32,688,628
	Issued Capital	Reserves	Accumulated Losses	Owners of parent	Non- controlling interest	Total
	\$	\$	\$	\$	\$	\$
Balance at 1 July 2016	44,552,216	4,371,541	(15,795,652)	33,128,105	(439,477)	32,688,628
(Loss)/profit after income tax expense for the year	-	-	(3,343,878)	(3,343,878)	(819,453)	(4,163,331)
Other comprehensive income for the year, net of tax	-	(761,137)	-	(761,137)	-	(761,137)
Total comprehensive income for the year	-	(761,137)	(3,343,878)	(4,105,015)	(819,453)	(4,924,468)
<i>Transactions with owners in their capacity as owners:</i>						
Shares issued during the period	2,352,116	-	-	2,352,116	-	2,352,116
Share issuance costs	(71,409)	-	-	(71,409)	-	(71,409)
Share option reserve on recognition of remuneration options	-	805,502	-	805,502	-	805,502
Acquisition (Note 19(b))	104,437	-	-	104,437	-	104,437
Balance at 30 June 2017	46,937,360	4,415,906	(19,139,530)	32,213,736	(1,258,930)	30,954,806

The above statement should be read in conjunction with the consolidated notes.

SOMNOMED LIMITED
ACN 003255221
CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 30 JUNE 2017

	NOTE	2017 \$	2016 \$
Cash flows from operating activities			
Receipts from customers (inclusive of GST)		49,011,553	43,061,131
Payments to suppliers and employees (inclusive of GST)		(50,677,585)	(40,846,460)
Interest received		124,235	55,935
Interest paid		(20,423)	(10,723)
Income tax paid		(1,117,450)	(154,860)
Net cash (outflow)/inflow from operating activities	21	<u>(2,679,670)</u>	<u>2,105,023</u>
Cash flows from investing activities			
Acquisition of subsidiary, net of cash acquired		(103,932)	(1,225,752)
Payments for intangible assets		(238,857)	(99,120)
Payments for property, plant and equipment		(2,392,392)	(1,907,974)
Net cash outflow from investing activities		<u>(2,735,181)</u>	<u>(3,232,846)</u>
Cash flows from financing activities			
Proceeds from issue of shares		2,352,116	10,707,689
Share issuance costs		(71,410)	(247,437)
Net cash inflow from financing activities		<u>2,280,706</u>	<u>10,460,252</u>
Net (decrease)/increase in cash and cash equivalents		(3,134,145)	9,332,429
Cash at beginning of the financial year		17,632,252	8,305,556
Exchange rate adjustment		(287,786)	(5,733)
Cash at the end of the financial year	20	<u>14,210,321</u>	<u>17,632,252</u>

The cash balances at 30 June 2017 and 30 June 2016 are represented by cash at bank and money market securities.

The above statement should be read in conjunction with the consolidated notes.

SOMNOMED LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 JUNE 2017

1. REPORTING ENTITY

SomnoMed Limited is a company domiciled and incorporated in Australia. The consolidated financial statements of the Company as at and for the year ended 30 June 2017 comprise the Company and its controlled entities (together referred to as the "Consolidated Entity"). The Consolidated Entity produces and sells devices for the oral treatment of sleep related disorders.

2. BASIS OF PREPARATION

a. Statement of compliance

The financial report is a general purpose financial report, which has been prepared in accordance with Australian Accounting Standards (AASBs) (including Australian Interpretations) adopted by the Australian Accounting Standards Board and the Corporations Act 2001 as appropriate for profit oriented entities. The financial report of the Consolidated Entity and the financial report of the Company comply with International Financial Reporting Standards and Interpretations adopted by the International Accounting Standards Board.

b. Basis of measurement

The consolidated financial statements have been prepared on the historical cost basis, except for derivative financial instruments and the contingent consideration payables, which are measured at fair value.

c. Functional and presentation currency

These consolidated financial statements are presented in Australian dollars, which is the Company's functional currency.

d. Use of judgements and estimates

The preparation of financial statements requires management to make judgements, estimates and assumptions that affect the application of accounting policies and reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised and in any future periods affected.

Management discussed with the Audit Committee the development, selection and disclosure of the Consolidated Entity's critical accounting policies and estimates and the application of these policies and estimates.

Key sources of estimation uncertainty

In particular, information about significant areas of estimation, uncertainty and critical judgments in applying accounting policies that have the most significant effect on the amounts recognised in the financial statements is described in the following areas:

Share-based payment transactions

The Consolidated Entity measures the cost of equity-settled transactions with employees by reference to the fair value of the equity instruments at the date at which they are granted. The fair value is determined by using either the Binomial or Black-Scholes model taking into account the terms and conditions upon which the instruments were granted. The accounting estimates and assumptions relating to equity-settled share-based payments would have no impact on the carrying amounts of assets and liabilities within the next annual reporting period but may impact profit or loss and equity.

Goodwill and other indefinite life intangible assets

The Consolidated Entity tests annually, or more frequently if events or changes in circumstances indicate impairment, whether goodwill and other indefinite life intangible assets have suffered any impairment, in accordance with the accounting policy stated in Note 3. The recoverable amounts of cash-generating units have been determined based on value-in-use calculations. These calculations require the use of assumptions, including estimated discount rates based on the current cost of capital and growth rates of the estimated future cash flows.

Income tax

The Consolidated Entity is subject to income taxes in the jurisdictions in which it operates. Significant judgement is required in determining the provision for income tax. There are many transactions and calculations undertaken during the ordinary course of business for which the ultimate tax determination is uncertain. The Consolidated Entity recognises liabilities for anticipated tax audit issues based on the Consolidated Entity's current understanding of the tax law. Where the final tax outcome of these matters is different from the carrying amounts, such differences will impact the current and deferred tax provisions in the period in which such determination is made.

SOMNOMED LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2017

2. BASIS OF PREPARATION (continued)

d. Use of judgements and estimates (continued)

Impairment of non-financial assets other than goodwill and other indefinite life intangible assets

The Consolidated Entity assesses impairment of non-financial assets other than goodwill and other indefinite life intangible assets at each reporting date by evaluating conditions specific to the Consolidated Entity and to the particular asset that may lead to impairment. If an impairment trigger exists, the recoverable amount of the asset is determined. This involves fair value less costs of disposal or value-in-use calculations, which incorporate a number of key estimates and assumptions.

Recovery of deferred tax assets

Deferred tax assets are recognised for deductible temporary differences only if the Consolidated Entity considers it is probable that future taxable amounts will be available to utilise those temporary differences and losses. Recoverability of the deferred tax assets is evaluated at each reporting date by review of future budgets and forecasts which includes predicted future tax profits. The deferred asset is reduced to the extent that it is no longer probable that the related tax benefit will be realised.

Employee benefits provision

As discussed, the liability for employee benefits expected to be settled more than 12 months from the reporting date are recognised and measured at the present value of the estimated future cash flows to be made in respect of all employees at the reporting date. In determining the present value of the liability, estimates of attrition rates and pay increases through promotion and inflation have been taken into account.

Lease make good provision

A provision has been made for the present value of anticipated costs for future restoration of leased premises. The provision includes future cost estimates associated with closure of the premises. The calculation of this provision requires assumptions such as application of closure dates and cost estimates. The provision recognised for each site is periodically reviewed and updated based on the facts and circumstances available at the time. Changes to the estimated future costs for sites are recognised in the statement of financial position by adjusting the asset and the provision. Reductions in the provision that exceed the carrying amount of the asset will be recognised in profit or loss.

Warranty provision

In determining the level of provision required for warranties the Consolidated Entity has made judgements in respect of the expected performance of the products, the number of customers who will actually claim under the warranty and how often, and the costs of fulfilling the conditions of the warranty. The provision is based on estimates made from historical warranty data associated with similar products and services. In the past the Company calculated the warranty provision as a percentage of sales. Beginning in FY2014, the provision is based on estimates made from historical warranty data associated with similar products and services as this approach is deemed to be more representative of the actual warranty claims.

Business combinations

Business combinations are initially accounted for on a provisional basis.

The fair value of assets acquired, liabilities and contingent liabilities assumed are initially estimated by the Consolidated Entity taking into consideration all available information at the reporting date. Fair value adjustments on the finalisation of the business combination accounting is retrospective, where applicable, to the period the combination occurred and may have an impact on the assets and liabilities, depreciation and amortisation reported.

Fair value measurement hierarchy

The consolidated entity is required to classify all assets and liabilities, measured at fair value, using a three level hierarchy, based on the lowest level of input that is significant to the entire fair value measurement, being: Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date; Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and Level 3: Unobservable inputs for the asset or liability. Considerable judgement is required to determine what is significant to fair value and therefore which category the asset or liability is placed in can be subjective.

The fair value of assets and liabilities classified as level 3 is determined by the use of valuation models. These include discounted cash flow analysis or the use of observable inputs that require significant adjustments based on unobservable inputs.

3. SIGNIFICANT ACCOUNTING POLICIES

The accounting policies set out below have been applied consistently to all periods presented in these consolidated financial statements and have been applied consistently by all entities in the Consolidated Entity.

SOMNOMED LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2017

3. SIGNIFICANT ACCOUNTING POLICIES (continued)

a. Basis of Consolidation

Controlled entities

Controlled entities are entities controlled by the Company. Control exists when the Company has power, directly or indirectly, to govern the financial and operating policies of an entity so as to obtain benefits from its activities. In assessing control, potential voting rights that presently are exercisable or convertible are taken into account. The financial statements of controlled entities are included in the consolidated financial statements from the date that control commences until the date that control ceases. Investments in controlled entities are carried at their cost of acquisition in the Company's financial statements.

Transactions eliminated on consolidation

Intra-group balances and any realised gains and losses or income and expenses arising from intra-group transactions, are eliminated in preparing the consolidated financial statements.

Business combinations

Business combinations occur where an acquirer obtains control over one or more businesses.

A business combination is accounted for by applying the acquisition method, unless it is a combination involving entities or businesses under common control. The business combination will be accounted for from the date that control is attained, whereby the fair value of the identifiable assets acquired and liabilities (including contingent liabilities) assumed is recognised (subject to certain limited exemptions).

When measuring the consideration transferred in the business combination, any asset or liability resulting from a contingent consideration arrangement is also included. Subsequent to initial recognition, contingent consideration classified as equity is not remeasured and its subsequent settlement is accounted for within equity. Contingent consideration classified as an asset or liability is remeasured in each reporting period to fair value, recognising any change to fair value in profit or loss, unless the change in value can be identified as existing at acquisition date.

All transaction costs incurred in relation to business combinations are recognised as expenses in profit or loss when incurred.

The acquisition of a business may result in the recognition of goodwill or a gain from a bargain purchase.

Goodwill

All business combinations are accounted for by applying the acquisition method. Goodwill represents the difference between the cost of the acquisition and the fair value of the net identifiable assets acquired.

Goodwill is stated at cost less any accumulated impairment losses. Goodwill is allocated to cash generating units and is tested annually for impairment. Negative goodwill arising on an acquisition is recognised directly in the statement of profit or loss and other comprehensive income.

b. Foreign Currency

Foreign currency transactions

Transactions in foreign currencies are translated to the respective functional currencies of controlled entities at the foreign exchange rate ruling at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies at the reporting date are translated to the functional currency at the foreign exchange rate ruling at that date. Non-monetary transactions denominated in foreign currencies that are stated at historical cost are translated using the exchange rate at the date of the transaction. Non-monetary assets and liabilities denominated in foreign currencies that are stated at fair value are translated to the functional currency at the foreign exchange rates ruling at the date the fair value was determined. Foreign exchange differences arising on translation are recognised in the statement of profit or loss and other comprehensive income.

Financial statements of foreign operations

The assets and liabilities of foreign operations, including goodwill and fair value adjustments arising on acquisition, generally are translated to the functional currency at foreign exchange rates ruling at the reporting date. The revenues and expenses of foreign operations are translated to the functional currency at rates approximating the foreign exchange rates ruling at the dates of transactions. Foreign currency differences arising from translation of controlled entities with a different functional currency to that of the Consolidated Entity are recognised in the foreign currency translation reserve (FCTR). When a foreign operation is disposed of, in part or in full, the relevant amount of its FCTR is transferred to profit or loss.

Foreign exchange gains and losses arising from a monetary item receivable from or payable to a foreign operation, the settlement of which is neither planned nor likely in the foreseeable future, are considered to form part of a net investment in a foreign operation and are recognised directly in equity in the FCTR.

SOMNOMED LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2017

3. SIGNIFICANT ACCOUNTING POLICIES (continued)

c. Financial Instruments

Derivative Financial Instruments

The Consolidated Entity does not currently hold, but held in previous years, derivative financial instruments to hedge its exposure to foreign exchange risk arising from operating, investing and financing activities. In accordance with its treasury policy, the Consolidated Entity does not hold or issue derivative financial instruments for trading purposes. However, derivatives are not hedge accounted and are accounted for as trading instruments.

Derivative financial instruments are recognised initially at fair value. Attributable transaction costs are recognised in the statement of profit or loss and other comprehensive income when incurred. Subsequent to initial recognition, derivative financial instruments are measured at fair value with changes in fair value accounted for in the statement of profit or loss and other comprehensive income.

Non-derivative financial assets and liabilities

Non-derivative financial instruments comprise investments in equity, trade and other receivables, cash and cash equivalents, loans, and trade and other payables.

Non-derivative financial instruments are recognised initially at fair value plus, for instruments not at fair value through the statement of profit or loss and other comprehensive income, any attributable transaction costs. Subsequent to initial recognition, non-derivative financial instruments are measured as described below.

Accounting for finance income is discussed in accounting policy of Note 28.

Determination of fair values

The fair value of forward exchange contracts is based upon the listed market price, if available. If a listed market price is not available, the fair value is estimated by discounting the difference between the contractual forward price and the current forward price for the residual maturity of the contract using a risk free interest rate based upon government bonds.

Other

Other non-derivative financial instruments are measured at amortised cost using the effective interest rate method, less any impairment losses.

d. Impairment

The carrying amounts of the Consolidated Entity's assets, other than inventories (see accounting policy of Note 10) are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, the asset's recoverable amount is estimated (see below). An impairment loss is recognised whenever the carrying amount of an asset or its cash generating unit exceeds its recoverable amount. Impairment losses are recognised in the statement of profit or loss and other comprehensive income of profit or loss unless the asset has previously been revalued, in which case the impairment loss is recognised as a reversal to the extent of that previous revaluation with any excess recognised through the statement of profit or loss and other comprehensive income of profit or loss. Impairment losses recognised in respect of cash generating units are allocated first to reduce the carrying amount of any goodwill allocated to the cash generating unit or a group of units and then, to reduce the carrying amount of the other assets in the unit or a group of units on a pro-rata basis.

Calculation of recoverable amount

Receivables

The recoverable amount of the Consolidated Entity's investments in receivables carried at amortised cost is calculated as the present value of estimated future cash flows, discounted at the original effective interest rate (i.e. the effective interest rate computed at initial recognition of these financial assets). Receivables with a short duration are not discounted. Impairment of receivables is not recognised until objective evidence is available that a loss event has occurred. Significant receivables are individually assessed for impairment. Impairment testing of significant receivables that are not assessed as impaired individually is performed by placing them into portfolios of significant receivables with similar risk profiles and undertaking a collective assessment of impairment. Non-significant receivables are not individually assessed. Instead, impairment testing is performed by placing non-significant receivables in portfolios of similar risk profiles, based on objective evidence from historical experience adjusted for any effects of conditions existing at each balance date. The allowance for impairment is calculated with reference to the profile of debtors in the Consolidated Entity's sales and marketing regions.

SOMNOMED LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2017

3. SIGNIFICANT ACCOUNTING POLICIES (continued)

d. Impairment (continued)

Other Assets

The recoverable amount of other assets is the greater of their fair value less costs to sell, and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. For the purpose of impairment testing, assets are grouped together into the smallest group of assets that generate cash flows from continuing use that are largely independent of the cash flows of other assets or groups of assets (cash generating units). The goodwill acquired in a business combination, for the purpose of impairment testing is allocated to the cash generating units that are expected to benefit from the synergies of the combination. For an asset that does not generate largely independent cash inflows, the recoverable amount is determined for the cash generating unit to which the asset belongs.

Reversals of Impairment

An impairment loss in respect of a receivable carried at amortised cost is reversed if the subsequent increase in recoverable amount can be related objectively to an event occurring after the impairment loss was recognised. An impairment loss in respect of goodwill is not reversed. In respect of other assets, an impairment loss is reversed when there is an indication that the impairment loss may no longer exist and there has been a change in the estimates used to determine the recoverable amount. An impairment loss is reversed only to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or realisation, if no impairment loss had been recognised.

e. New Accounting Standards and Interpretations not yet mandatory or early adopted

Australian Accounting Standards and Interpretations that have recently been issued or amended but are not yet mandatory, have not been early adopted by the consolidated entity for the annual reporting period ended 30 June 2017. The consolidated entity's assessment of the impact of these new or amended Accounting Standards and Interpretations, most relevant to the consolidated entity, are set out below.

AASB 9 Financial Instruments

This standard is applicable to annual reporting periods beginning on or after 1 January 2018. The standard replaces all previous versions of AASB 9 and completes the project to replace IAS 39 'Financial Instruments: Recognition and Measurement'. AASB 9 introduces new classification and measurement models for financial assets. A financial asset shall be measured at amortised cost, if it is held within a business model whose objective is to hold assets in order to collect contractual cash flows, which arise on specified dates and solely principal and interest. All other financial instrument assets are to be classified and measured at fair value through profit or loss unless the entity makes an irrevocable election on initial recognition to present gains and losses on equity instruments (that are not held-for-trading) in other comprehensive income ('OCI'). For financial liabilities, the standard requires the portion of the change in fair value that relates to the entity's own credit risk to be presented in OCI (unless it would create an accounting mismatch). New simpler hedge accounting requirements are intended to more closely align the accounting treatment with the risk management activities of the entity. New impairment requirements will use an 'expected credit loss' ('ECL') model to recognise an allowance. Impairment will be measured under a 12-month ECL method unless the credit risk on a financial instrument has increased significantly since initial recognition in which case the lifetime ECL method is adopted. The standard introduces additional new disclosures. The consolidated entity will adopt this standard from 1 July 2018 but the impact of its adoption is yet to be assessed by the consolidated entity.

AASB 15 Revenue from Contracts with Customers

This standard is applicable to annual reporting periods beginning on or after 1 January 2017. The standard provides a single standard for revenue recognition. The core principle of the standard is that an entity will recognise revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard will require: contracts (either written, verbal or implied) to be identified, together with the separate performance obligations within the contract; determine the transaction price, adjusted for the time value of money excluding credit risk; allocation of the transaction price to the separate performance obligations on a basis of relative stand-alone selling price of each distinct good or service, or estimation approach if no distinct observable prices exist; and recognition of revenue when each performance obligation is satisfied. Credit risk will be presented separately as an expense rather than adjusted to revenue. For goods, the performance obligation would be satisfied when the customer obtains control of the goods. For services, the performance obligation is satisfied when the service has been provided, typically for promises to transfer services to customers.

SOMNOMED LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2017

3. SIGNIFICANT ACCOUNTING POLICIES (continued)

e. New Accounting Standards and Interpretations not yet mandatory or early adopted (continued)

AASB 15 Revenue from Contracts with Customers (continued)

For performance obligations satisfied over time, an entity would select an appropriate measure of progress to determine how much revenue should be recognised as the performance obligation is satisfied. Contracts with customers will be presented in an entity's statement of financial position as a contract liability, a contract asset, or a receivable, depending on the relationship between the entity's performance and the customer's payment. Sufficient quantitative and qualitative disclosure is required to enable users to understand the contracts with customers; the significant judgments made in applying the guidance to those contracts; and any assets recognised from the costs to obtain or fulfil a contract with a customer. The consolidated entity will adopt this standard from 1 July 2017 but the impact of its adoption is yet to be assessed by the consolidated entity. As the Group is exposed to transactions around goods returned and transactions where another party is involved in providing goods (principle vs agent consideration), the directors anticipate that the adoption of AASB 15 may have an impact on the Group's financial statements in future periods.

AASB 16 Leases

This standard is applicable to annual reporting periods beginning on or after 1 January 2019. The standard replaces AASB 117 'Leases' and for lessees will eliminate the classifications of operating leases and finance leases. Subject to exceptions, a 'right-of-use' asset will be capitalised in the statement of financial position, measured as the present value of the unavoidable future lease payments to be made over the lease term. The exceptions relate to short-term leases of 12 months or less and leases of low-value assets (such as personal computers and small office furniture) where an accounting policy choice exists whereby either a 'right-of-use' asset is recognised or lease payments are expensed to profit or loss as incurred. A liability corresponding to the capitalised lease will also be recognised, adjusted for lease prepayments, lease incentives received, initial direct costs incurred and an estimate of any future restoration, removal or dismantling costs. Straight-line operating lease expense recognition will be replaced with a depreciation charge for the leased asset (included in operating costs) and an interest expense on the recognised lease liability (included in finance costs). In the earlier periods of the lease, the expenses associated with the lease under AASB 16 will be higher when compared to lease expenses under AASB 117. However EBITDA (Earnings Before Interest, Tax, Depreciation and Amortisation) results will be improved as the operating expense is replaced by interest expense and depreciation in profit or loss under AASB 16. For classification within the statement of cash flows, the lease payments will be separated into both a principal (financing activities) and interest (either operating or financing activities) component. For lessor accounting, the standard does not substantially change how a lessor accounts for leases. The consolidated entity will adopt this standard from 1 July 2019 but the impact of its adoption is yet to be assessed by the consolidated entity. As the Group operates its sleep centres through operating property leases, the directors anticipate that the adoption of AASB 16 will have an impact due to the amount of property leases which will be brought onto the financial statements.

f. New, revised or amending Accounting Standards and Interpretations adopted

The consolidated entity has adopted all of the new, revised or amending Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period.

Any new, revised or amending Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.

g. Current and non-current classification

Assets and liabilities are presented in the statement of financial position based on current and non-current classification.

An asset is current when: it is expected to be realised or intended to be sold or consumed in normal operating cycle; it is held primarily for the purpose of trading; it is expected to be realised within twelve months after the reporting period; or the asset is cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. All other assets are classified as non-current.

A liability is current when: it is expected to be settled in normal operating cycle; it is held primarily for the purpose of trading; it is due to be settled within twelve months after the reporting period; or there is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period. All other liabilities are classified as non-current.

Deferred tax assets and liabilities are always classified as non-current.

SOMNOMED LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2017

3. SIGNIFICANT ACCOUNTING POLICIES (continued)

h. Fair value measurement

When an asset or liability, financial or non-financial, is measured at fair value for recognition or disclosure purposes, the fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date; and assumes that the transaction will take place either: in the principle market; or in the absence of a principal market, in the most advantageous market.

Fair value is measured using the assumptions that market participants would use when pricing the asset or liability, assuming they act in their economic best interest. For non-financial assets, the fair value measurement is based on its highest and best use. Valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, are used, maximising the use of relevant observable inputs and minimising the use of unobservable inputs.

Assets and liabilities measured at fair value are classified, into three levels, using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. Classifications are reviewed each reporting date and transfers between levels are determined based on a reassessment of the lowest level input that is significant to the fair value measurement.

For recurring and non-recurring fair value measurements, external valuers may be used when internal expertise is either not available or when the valuation is deemed to be significant. External valuers are selected based on market knowledge and reputation. Where there is a significant change in fair value of an asset or liability from one period to another, an analysis is undertaken, which includes a verification of the major inputs applied in the latest valuation and a comparison, where applicable, with external sources of data.

Fair value measurement hierarchy

The Consolidated Entity is required to classify all assets and liabilities, measured at fair value, using a three level hierarchy, based on the lowest level of input that is significant to the entire fair value measurement, being: Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date; Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and Level 3: Unobservable inputs for the asset or liability. Considerable judgement is required to determine what is significant to fair value and therefore which category the asset or liability is placed in can be subjective.

The fair value of assets and liabilities classified as level 3 is determined by the use of valuation models. These include discounted cash flow analysis or the use of observable inputs that require significant adjustments based on unobservable inputs.

4. FINANCIAL RISK MANAGEMENT

Overview

The Company and Consolidated Entity have exposure to the following risks from the use of financial instruments:

- Credit risk
- Liquidity risk
- Market risk

This note presents information about the Company's and the Consolidated Entity's exposure to each of the above risks, their objectives, policies and processes for measuring and managing risk, and the management of capital. Further quantitative disclosures are included throughout these consolidated financial statements. The Board of Directors has overall responsibility for the establishment and oversight of the risk management and monitors operational and financial risk management throughout the Consolidated Entity.

Monitoring risk management includes ensuring appropriate policies and procedures are published and adhered to. The Management reports to the Audit Committee.

The Board aims to manage the impact of short-term fluctuations on the Company's and the Consolidated Entity's earnings. Over the longer term, permanent changes in market rates will have an impact on earnings.

The Company and the Consolidated Entity are exposed to risks from movements in exchange rates and interest rates that affect revenues, expenses, assets, liabilities and forecast transactions. Financial risk management aims to limit these market risks through ongoing operational and finance activities.

Exposure to credit, foreign exchange and interest rate risks arises in the normal course of the Company's and the Consolidated Entity's business. Derivative financial instruments are used to hedge exposure to fluctuations in foreign exchange rates.

The Audit Committee oversees adequacy of the Company's risk management framework in relation to the risks faced by the Company and the Consolidated Entity.

**SOMNOMED LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2017**

5. REVENUE

Significant Accounting Policies

Income Recognition

Revenues are recognised at fair value of the consideration received net of the amount of goods and services tax (GST).

Sales revenue

Sales revenue comprises revenue earned (net of returns, discounts and allowances) from the provision of products and services. Revenue from the sale of goods is recognised upon dispatch of goods to customers.

Other income

Other income is recognised on a systematic basis over the periods necessary to match it with the related costs for which it is intended to compensate or, if the costs have already been incurred, in the period in which it becomes receivable. The income is deemed to be receivable when the entitlement is confirmed.

Goods and Services Tax

Revenues, expenses and assets are recognised net of the amount of GST, except where the amount of GST incurred is not recoverable from the taxation authority. In these circumstances, the GST is recognised as part of the cost of acquisition of the asset or as part of the expense. Receivables and payables are stated with the amount of GST included. The net amount of GST recoverable from, or payable to, the relevant taxation authority is included as a current asset or liability in the balance sheet. Cash flows are included in the statement of cash flows on a gross basis. The GST components of cash flows arising from investing and financing activities, which are recoverable from, or payable to, the relevant taxation authority are classified as operating cash flows.

	2017	2016
	\$	\$
Interest received	124,236	55,935
Revenue from sale of goods, net of discounts	49,326,974	44,084,153
	49,451,210	44,140,088

6. (LOSS)/PROFIT FOR THE YEAR

Significant Accounting Policies

Employee benefits

Wages, salaries and annual leave

Liabilities for employee benefits for wages, salaries and annual leave expected to settle within 12 months of the year end represent present obligations resulting from employees' services provided up to reporting date, calculated at undiscounted amounts based on remuneration wage and salary rates that the Consolidated Entity expects to pay as at reporting date including related on-costs, such as workers' compensation insurance and payroll tax.

Other long-term employee benefits

The liability for annual leave and long service leave not expected to be settled within 12 months of the reporting date are recognised in non-current liabilities, provided there is an unconditional right to defer settlement of the liability. The liability is measured as the present value of expected future payments to be made in respect of services provided by employees up to the reporting date using the projected unit credit method. Consideration is given to expected future wage and salary levels, experience of employee departures and periods of service. Expected future payments are discounted using market yields at the reporting date on national government bonds with terms to maturity and currency that match, as closely as possible, the estimated future cash outflows.

**SOMNOMED LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2017**

6. (LOSS)/PROFIT FOR THE YEAR (continued)

Significant Accounting Policies

Share based payments

The Company has granted options to certain directors and employees. The fair value of options and shares granted is recognised as a share and option expense with a corresponding increase in equity. The fair value is measured at the date the options or shares are granted taking into account market based criteria and expensed over the vesting period after which the employees become unconditionally entitled to the options and shares. The fair value of the options granted is measured using the Black-Scholes method, taking into account the terms and conditions attached to the options. The fair value of the performance shares granted is measured using the weighted average share price of ordinary shares in the Company, taking into account the terms and conditions attached to the shares. The amount recognised as an expense is adjusted to reflect the actual number of options and shares that vest except where forfeiture is due to market related conditions.

Leased assets – Operating leases

Payments made under operating leases are expensed on a straight-line basis over the term of the lease, except where an alternative basis is more representative of the pattern of benefits to be derived from the leased property. Minimum lease payments include fixed rate increases.

	2017	2016
	\$	\$
(Loss)/profit before income tax includes the following specific expenses:		
Operating lease rentals	1,225,848	905,876
Employee benefits expense	19,951,308	16,858,578
Depreciation	1,123,174	872,932
Amortisation of intellectual property	109,140	147,122
Research and development expenditure	889,468	732,519

7. INCOME TAX EXPENSE

Significant Accounting Policies

Income tax expense in the statement of profit or loss for the periods presented comprises current and deferred tax. Income tax is recognised in the statement of profit or loss except to the extent that it relates to items recognised directly in equity, in which case it is recognised in equity. Current tax is the expected tax payable on the taxable income for the year, using tax rates enacted or substantially enacted at reporting date, and any adjustment to tax payable in respect of previous years. Deferred tax is calculated using the balance sheet method, providing for temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Temporary differences are not provided for the initial recognition of goodwill and other assets or liabilities in a transaction that affects neither accounting nor taxable profit or differences relating to investments in subsidiaries to the extent that it is probable that they will not reverse in the foreseeable future.

Deferred tax is measured at the tax rates that are expected to be applied to the temporary differences when they reverse, based upon the laws that have been enacted at reporting date. A deferred tax asset is recognised only to the extent that it is probable that future taxable profits will be available against which the asset can be realised. Deferred tax assets are reviewed at each reporting date and reduced to the extent that it is no longer probable that the related tax benefit will be realised. Additional income taxes that arise from the distribution of dividends are recognised at the same time as the liability to pay the related dividend is recognised.

Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority on the same taxable entity or on a different tax entity but they intend to settle current tax liabilities and assets on a net basis or their tax assets and liabilities will be realised simultaneously.

SOMNOMED LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2017

7. INCOME TAX EXPENSE (continued)

	NOTE	2017 \$	2016 \$
a. The components of tax expense comprise:			
Current tax		301,133	423,587
Deferred tax	7d	98,202	-
		<u>399,335</u>	<u>423,587</u>
b. The prima facie tax on profit before income tax is reconciled to the income tax expense/(benefit) as follows:			
Prima facie income tax expense calculated using the Australian tax rate of 30% (2016: 30%)		(1,129,199)	147,232
(Increase)/decrease in income tax expense due to non-(deductible)/assessable and other items		1,528,534	276,355
Income tax expense		<u>399,335</u>	<u>423,587</u>
c. Deferred tax assets			
Recognised deferred tax assets			
Plant and equipment		(148,276)	(181,124)
Accruals		600,703	460,230
Provisions		92,330	71,104
Deferred revenue		80,702	818
Tax losses carried forward		2,843,303	2,711,209
Deferred tax assets		<u>3,468,762</u>	<u>3,062,237</u>
While the consolidated entity recorded trading losses in various segments the strategies implemented by management around growth and cost efficiencies has led management to believe the loss making segments should return to generating sufficient taxable profits and therefore recoup the tax losses being recognised.			
d. Movement in temporary differences and tax losses during the year			
Carrying amount at beginning of financial year		3,062,237	2,986,551
Recognised in the statement of profit or loss and other comprehensive income	7a	(98,202)	-
Underprovision in respect of prior year		584,103	-
Foreign exchange adjustment		(79,376)	75,686
Carrying amount at end of financial year		<u>3,468,762</u>	<u>3,062,237</u>
e. Deferred tax assets not brought to account			
Deferred tax assets not brought to account, the benefits of which will only be realised if the conditions for deductibility set out in Note 3(d) occur			
Tax losses		1,196,997	658,705
Temporary differences		<u>2,519,081</u>	<u>743,084</u>

SOMNOMED LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2017

7. INCOME TAX EXPENSE (continued)

	2017	2016
	\$	\$
<i>Franking credits</i>		
Franking credits available for subsequent financial years based on a tax rate of 30%	33,447	33,447

The above amounts represent the balance of the franking account as at the end of the financial year, adjusted for:

- franking credits that will arise from the payment of the amount of the provision for income tax at the reporting date
- franking debits that will arise from the payment of dividends recognised as a liability at the reporting date
- franking credits that will arise from the receipt of dividends recognised as receivables at the reporting date

8. CASH AND CASH EQUIVALENTS

Significant Accounting Policies

Cash and cash equivalents comprise cash balances and call deposits with an original maturity of three months or less.

Cash at bank and on deposit	14,210,321	17,632,252
	14,210,321	17,632,252

9. TRADE AND OTHER RECEIVABLES

Significant Accounting Policies

Trade and other receivables are stated at amortised cost less impairment losses (see accounting policy 3(d)).

Current

Trade receivables	6,884,771	6,181,721
Less provision for impairment	(266,242)	(122,238)
	6,618,529	6,059,483
Other receivables	3,578,179	1,787,682
	10,196,708	7,847,165

10. INVENTORIES

Significant Accounting Policies

Inventories are measured at the lower of cost and net realisable value. Net realisable value is the estimated selling price in the ordinary course of business less estimated costs of completion and selling, marketing and distribution expenses. Cost is based on the first-in-first-out principle and includes expenditure incurred in acquiring the inventories and bringing them to their existing condition and location.

Raw materials and consumables	1,947,565	1,690,632
-------------------------------	-----------	-----------

SOMNOMED LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2017

11. PROPERTY, PLANT AND EQUIPMENT

Significant Accounting Policies

Owned assets

Items of property, plant and equipment are stated at cost less accumulated depreciation (see below) and impairment losses (see accounting policy 3(d)). An asset's cost is determined as the consideration provided plus incidental costs directly attributable to the acquisition. Subsequent costs in relation to replacing a part of property, plant and equipment are recognised in the carrying amount of the item if it is probable that future economic benefits embodied within the part will flow to the Consolidated Entity and its cost can be measured reliably. All other costs are recognised in the statement of profit or loss and other comprehensive income as incurred.

Depreciation

Depreciation is recognised in the statement of profit or loss on a straight-line basis. Items of property, plant and equipment, including leasehold assets, are depreciated using the straight-line method over their estimated useful lives, taking into account estimated residual values. Assets are depreciated from the date of acquisition or, in respect of internally constructed assets, from the time an asset is completed and held ready for use. Depreciation rates and methods, useful lives and residual values are reviewed at each balance sheet date. When changes are made, adjustments are reflected prospectively in current and future financial periods only.

The estimated useful lives in the current and comparative periods are as follows:

Leasehold improvements	1 – 3 years
Plant & equipment	3 – 20 years
Software	2 – 5 years

	2017	2016
	\$	\$
Property, plant and equipment –at cost	8,586,149	7,733,553
Accumulated depreciation	(4,094,726)	(4,160,588)
	<u>4,491,423</u>	<u>3,572,965</u>
Movements in the carrying amounts of plant and equipment during the current financial year:		
Balance at the beginning of the year	3,572,965	2,104,721
Additions	2,331,865	2,369,326
Disposals	(70,698)	(8,019)
Depreciation expense	(1,123,174)	(872,932)
Effect of movements in foreign exchange	(219,535)	(20,131)
Carrying amount at the end of the year	<u>4,491,423</u>	<u>3,572,965</u>

Included in property, plant and equipment are capitalised lease incentives of \$249,954 (2016: \$456,260). Lease incentives are recognised as an asset and a liability in the financial statements and amortised over the term of the lease.

SOMNOMED LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2017

12. INTANGIBLE ASSETS

Significant Accounting Policies

Goodwill

Goodwill is stated at cost less any accumulated impairment losses. Goodwill is allocated to cash generating units and is tested annually for impairment. Negative goodwill arising on an acquisition is recognised directly in the statement of profit or loss and other comprehensive income.

Other intangible assets

Intellectual property, acquired is stated at cost less accumulated amortisation (see below) and impairment losses (see accounting policy 3(d)).

Subsequent expenditure

Subsequent expenditure on capitalised intangible assets is capitalised only when it increases the future economic benefits embodied in the specific asset to which it relates. All other expenditure is expensed as incurred.

Amortisation

Amortisation is recognised in the statement of profit or loss and other comprehensive income on a straight-line basis over the estimated useful lives of the intangible assets from the date they are available for use unless such lives are indefinite. Intangible assets with an indefinite useful life are systematically tested for impairment annually. The estimated useful lives for the current and comparative periods are as follows:

Patents 10 years

Product development expenditure capitalised 5 years

Research and development expenditure

Research and development expenditure during the research phase of a project is recognised as an expense when incurred. Development costs are capitalised only when technical feasibility studies identify that the project is expected to deliver future economic benefits and these benefits can be measured reliably. Development costs have a finite life and are amortised on a systematic basis based on the future economic benefits over the useful life of the project.

	2017	2016
	\$	\$
Patents and trademarks – at cost	1,098,302	911,459
Accumulated amortisation	(688,114)	(642,975)
	410,188	268,484
Product development expenditure capitalised	462,944	462,944
Accumulated amortisation	(411,262)	(347,038)
	51,682	115,906
Goodwill	6,170,660	6,237,531
	6,632,530	6,621,921
Movements in patents and trademarks		
Balance at beginning of year	268,484	156,314
Additions	184,323	160,538
Amortisation expense	(44,916)	(48,958)
Foreign currency translation difference	2,297	590
Balance at end of year	410,188	268,484

SOMNOMED LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2017

12. INTANGIBLE ASSETS (continued)

	2017 \$	2016 \$
Movements in product development expenditure capitalised		
Balance at beginning of year	115,906	248,297
Additions	-	15,616
Amortisation expense	(64,224)	(98,164)
Impairment	-	(49,843)
Balance at end of year	51,682	115,906
 Movements in goodwill		
Balance at beginning of year	6,237,531	5,476,614
Goodwill arising on the acquisition of Strong Dental Ltd	-	295,256
Goodwill arising on the acquisition of 50% holding in SMH Biomaterial AG	-	311,159
Impairment of goodwill SomnoMed Korea (refer below)	(40,000)	-
Foreign currency translation difference	(26,871)	154,502
Balance at end of year	6,170,660	6,237,531

Intangible assets, other than goodwill, have finite useful lives. The current amortisation charges for intangible assets are included under depreciation and amortisation expense per the consolidated statement of profit or loss and other comprehensive income. Goodwill has an indefinite useful life.

In November 2013 SomnoMed acquired various intangible assets enabling it to sell SomnoDent MAS devices in the South Korean market, including registration approvals, customer information, hospital coding access and marketing materials. During the year, management undertook a review for indicators of impairment and determined that the total goodwill of \$175,000 recognised in relation to the acquisition was impaired by \$40,000 due to the challenging sales environment.

Goodwill is allocated to cash generating units, which are based on the Group's geographic reporting segments.

Asia Pacific Segment	135,000	175,000
European Segment	5,761,624	5,777,455
North American Segment	274,036	285,076
	6,170,660	6,237,531

Impairment Test

The recoverable amount of the Consolidated Entity's goodwill has been determined by a value-in-use calculation using a discounted cash flow model, based on a 5 year projection period approved by management.

European division

Management believes that no reasonably possible changes in any of the key assumptions would cause the carrying value of the cash generating unit to materially exceed its recoverable amount.

The European cash generating unit (CGU) has a revenue growth per annum range of between 10% (2016: 8%) and 45% (2016: 40%) due to the differing stages of development these various markets are in. More established markets are experiencing lower growth rates than those in their infancy and considered to still be developing when it comes to Sleep Disordered Breathing treatment. The average growth of total costs per annum ranges between 9% (2016: 10%) and 21% (2016: 22%) due to the differing costs of business in different European markets. A similar range (7-14%) (2016: 10-11%) is seen for the average growth of operating costs per annum. The average discount rate used was 8.2% (2016: 6%). Based on the above, no impairment has been applied as the carrying amount of goodwill did not exceed its recoverable amount for the European business segment.

**SOMNOMED LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2017**

12. INTANGIBLE ASSETS (continued)

Asia Pacific Division

Goodwill in relation to acquisition of intangible assets in South Korea was impaired to \$135,000 (2016: \$175,000), representing 2% (2016: 3%) of total goodwill at 30 June 2017. The growth of revenue and expenses is expected to be 53% (2016: 58%) and 25% (2016: 28%) respectively per annum with a discount rate of 16% (2016: 16%) applied in the valuation. The growth of revenue and expenses varies due to the stage of development the market is in.

North America Division

Goodwill due to acquisition in SomnoMed Canada Inc. is \$274,036, representing 4 per cent of total goodwill at 30 June 2017. The growth of revenue and expenses is expected to be 25% and 11% per annum respectively with a discount rate of 16% applied in the valuation. The growth of revenue and expenses varies due to the stage of development the market is in. The recoverable amount of SomnoMed Canada Inc. exceeded the carrying amount by \$10,552. The impairment test indicated that no impairment was required.

Sensitivity

(a) Revenue would need to decrease by 3-79% (2016: 10-64%) for different CGUs before goodwill would need to be impaired, with all other assumptions remaining constant.

(b) The discount rate would be required to increase by 8-307% (2016: 15-180%) for the different CGUs before goodwill would need to be impaired, with all other assumptions remaining constant.

The following key assumptions were used for each CGU in the year of 2017:

	Decrease in revenue	Increase in discount rate
European division		
SomnoMed Germany GmbH	58%	235%
SomnoMed Nordic AB	39%	307%
Goedegebuure Slaaptechniek BV	44%	92%
SomnoMed France	6%	8%
SMH Biomaterial AG	79%	-*
Asia Pacific Division		
SomnoMed Korea	-	-
North America Division		
SomnoMed Canada	3%	4%

* The goodwill of SMH Biomaterial AG is not sensitive to changes in discount rates.

** The goodwill of SomnoMed Korea has been impaired. See above for further details.

13. TRADE AND OTHER PAYABLES

Significant Accounting Policies

Trade and other payables are stated at amortised cost.

	2017	2016
	\$	\$
CURRENT		
Trade payables, other payables and accruals	7,667,669	6,065,330
Income received in advance	100,100	17,233
Deferred rent	237,613	2,490
	<u>8,005,382</u>	<u>6,085,053</u>

SOMNOMED LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2017

14. PROVISIONS

Significant Accounting Policies

A provision is recognised in the balance sheet when the Consolidated Entity has a present legal or constructive obligation as a result of a past event that can be measured reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation.

Warranties

Provisions for warranty claims are made for claims in relation to sales made prior to the reporting date, based on historical claim rate, respective product populations and average costs of returns and repairs. Warranty periods on MAS devices are dependent on individual market and regulatory conditions in different countries.

Make good lease costs

The Consolidated Entity has an operating lease over its premises that require the premises to be returned to the lessor in its original condition. The operating lease payments do not include an element for the repairs/overhauls. A provision for make good lease costs is recognised at the time it is determined that it is probable that such costs will be incurred in a future period, measured at the expected cost of returning the asset to the lessor in its original condition. An offsetting asset of the same value is also recognised and is classified in property, plant and equipment. This asset is amortised to the statement of profit or loss and other comprehensive income over the life of the lease.

	2017	2016
	\$	\$
CURRENT		
Warranty	210,801	200,381
Lease make good	67,212	67,212
Employee entitlements	1,269,342	669,227
	1,547,355	936,820

Amounts not expected to be settled within the next 12 months

The current provision for employee benefits includes all unconditional entitlements where employees have completed the required period of service and also those where employees are entitled to pro-rata payments in certain circumstances. The entire amount is presented as current, since the Consolidated Entity does not have an unconditional right to defer settlement. However, based on past experience, the Consolidated Entity does not expect all employees to take the full amount of accrued leave or require payment within the next 12 months.

The following amounts reflect leave that is not expected to be taken within the next 12 months:

Employee benefits obligation expected to be settled after 12 months	417,905	126,828
NON CURRENT		
Employee entitlements	254,839	161,217

Movements in Provisions

2017	Warranty	Lease make good	Employee entitlement
	\$	\$	\$
Balance at the beginning of the year	200,381	67,212	830,444
Additional provisions recognised	20,660	-	1,221,997
Amounts used	(5,836)	-	(488,378)
Reversal	-	-	(2,067)
Effect of movement in foreign exchange	(4,405)	-	(37,815)
Balance at end of year	210,800	67,212	1,524,181

SOMNOMED LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2017

15. ISSUED CAPITAL	2017	2016
	\$	\$
Issued and fully paid ordinary shares		
57,867,419 (2016: 56,712,981) ordinary shares		
Balance of issued capital at the beginning of year	51,282,286	38,101,311
Shares issued during period:		
- 200,000 pursuant to exercise of options at \$1.23 on 25 August 2016	246,000	-
- 526,500 pursuant to issue of shares at \$3.44 on 31 October 2016	1,811,160	-
- 27,938 pursuant to acquisition of subsidiary at \$3.738158 on 3 January 2017	104,437	-
- 400,000 pursuant to exercise of options at \$3.00 on 4 May 2017	1,200,000	-
- 112,694 pursuant to acquisition of subsidiary at \$2.676 on 31 July 2015	-	301,569
- 37,779 pursuant to acquisition of subsidiary at \$2.51 on 31 July 2015	-	94,899
- 838,000 pursuant to issue of shares at \$2.40 on 13 October 2015	-	2,011,200
- 18,125 pursuant to exercise of options at 87 cents on 30 October 2015	-	43,500
- 18,125 pursuant to exercise of options at 87 cents on 30 October 2015	-	43,500
- 45,313 pursuant to exercise of options at 87 cents on 30 October 2015	-	108,750
- 10,000 pursuant to exercise of options at 87 cents on 30 October 2015	-	8,700
- 50,000 pursuant to exercise of options at 87 cents on 30 October 2015	-	43,500
- 200,000 pursuant to exercise of options at 92 cents on 30 October 2015	-	184,000
- 40,000 pursuant to issue of shares at \$2.40 on 6 November 2015	-	96,000
- 12,454 pursuant to acquisition of subsidiary at \$2.6065 on 14 January 2016	-	32,461
- 50,159 pursuant to acquisition of subsidiary at \$2.5737 on 28 April 2016	-	129,094
- 1,613,983 pursuant to issue of shares at \$2.50 on 16 May 2016	-	4,034,958
- 2,587,312 pursuant to issue of shares at \$2.50 on 16 May 2016	-	6,468,280
Less issue costs	(71,410)	(419,436)
Balance of issued capital at end of year	54,572,473	51,282,286
Less shares issued but not recorded in accounts		
- 25,000 shares issued at 60 cents	-	(15,000)
- 125,000 shares issued at 80 cents	-	(100,000)
- 150,000 shares issued at 79 cents	-	(118,500)
- 150,000 shares issued at \$1.24	-	(186,000)
- 182,500 shares issued at 58 cents	-	(105,850)
- 60,000 shares issued at 99 cents	-	(59,400)
- 942,000 shares issued at \$1.18	-	(1,111,560)
- 900,334 shares issued at \$1.18	(1,062,393)	-
- 125,000 shares issued at \$1.03	(128,750)	(128,750)
- 40,000 shares issued at \$1.37	-	(54,800)
- 15,000 shares issued at \$1.37	(20,550)	-
- 1,139,000 shares issued at \$2.09	-	(2,380,510)
- 1,134,000 shares issued at \$2.09	(2,370,060)	-
- 50,000 shares issued at \$2.70	(135,000)	(135,000)
- 838,000 shares issued at \$2.40	(2,011,200)	(2,011,200)
- 40,000 shares issued at \$2.40	(96,000)	(96,000)
- 50,000 shares issued at \$0.87	-	(43,500)
- 200,000 shares issued at \$0.92	-	(184,000)
- 526,500 shares issued at \$3.44	(1,811,160)	-
Total advances to executives to acquire shares in the Company	(7,635,113)	(6,730,070)
Issued share capital recorded in the Company accounts	46,937,360	44,552,216

Ordinary shares participate in dividends and the proceeds on winding up of the Company in proportion to the number of shares held.

At shareholders' meetings each ordinary share is entitled to one vote when a poll is called, otherwise each shareholder has one vote on a show of hands.

At 30 June 2017 there were 4,803,834 (2016: 4,816,500) unissued ordinary shares for which options were outstanding (including 3,628,834 (2016: 4,116,500) issued ordinary shares which are treated as options in these accounts).

SOMNOMED LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2017

15. ISSUED CAPITAL (continued)

Significant Accounting Policies

Ordinary shares

Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of ordinary shares and share options are recognised as a deduction from equity, net of any income tax benefit.

Capital Risk Management

The Consolidated Entity's objectives when managing capital are to safeguard its ability to continue as a going concern, to provide returns to shareholders, to provide benefits to other stakeholders and to maintain an optimal capital structure to reduce the cost of capital.

The Board aims to maintain and develop a capital base appropriate to the Consolidated Entity. In order to maintain or adjust the capital structure, the Consolidated Entity can issue new shares. The Board of Directors undertakes periodic reviews of the Consolidated Entity's capital management position to assess whether the capital management structure is appropriate to meet the Consolidated Entity's medium and long-term strategic requirements. Neither the Company nor any of its subsidiaries is subject to externally imposed capital requirements. There were no significant changes in the Consolidated Entity's approach to capital management during the year.

16. RESERVES

	2017	2016
	\$	\$
Share based payment reserve	3,311,165	2,505,660
Foreign currency translation reserve	4,076,568	1,837,708
Capital reserve	28,173	28,173
	4,415,906	4,371,541

The share based payment reserve records the fair value of share based payments as remuneration.

The foreign currency translation reserve records exchange differences arising on translation of foreign controlled subsidiaries.

The capital reserve records profits which will be distributed back to investors in SMH Biomaterial AG, an entity which SomnoMed Ltd owns 100% (2016: 100%).

17. REMUNERATION OF AUDITORS

Remuneration of BDO East Coast Partnership (Australia):

- Auditing or reviewing the financial report	100,000	88,000
- Other services (taxation)	160,000	13,000

Remuneration of other auditors (paid to BDONetwork firms)

- Auditing or reviewing the financial reports of subsidiaries	252,000	219,000
- Other services (taxation)	137,000	33,000

Total auditors' remuneration included in operating result	649,000	353,000
---	---------	---------

**SOMNOMED LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2017**

18. SEGMENT OPERATIONS

Significant Accounting Policies

An operating segment is a component of the Consolidated Entity that engages in business activities from which it may earn revenues and incur expenses, including revenues and expenses that relate to transactions with any of the Consolidated Entity's other components if separately reported and monitored. An operating segment's operating results are reviewed regularly by the Board of Directors to make decisions about resources to be allocated to the segment and assess its performance, and for which discrete financial information is available.

Segment results that are reported to the Board of Directors include items directly attributable to a segment as well as those that can be allocated on a reasonable basis. Unallocated items comprise mainly corporate head office results.

Primary Reporting – Business Segments

The Consolidated Entity produces and sells devices for the oral treatment of sleep related disorders primarily in the Asia Pacific region, North America and Europe.

The Consolidated Entity has identified its operating segments based on the internal reports that are reviewed and used by the Board of Directors (chief operating decision makers) in assessing performance and determining the allocation of resources.

The Consolidated Entity is managed primarily on the basis of geographical segments and the operating segments are therefore determined on the same basis.

SomnoMed's operations during the period related to the production and sale of products treating sleep disordered breathing, which is the only business segment.

Basis of accounting for purposes of reporting by operating segments

Accounting policies adopted

Unless stated otherwise, all amounts reported to the Board of Directors as the chief decision maker with respect to operating segments are determined in accordance with accounting policies that are consistent to those adopted in the annual financial statements of the Consolidated Entity.

Unallocated items

The following items of revenue and expenses are not allocated to operating segments as they are not considered part of the core operations of any segment:

- derivatives and foreign exchange gains and losses;
- interest and other income;
- corporate, research and development expenses;
- income tax expense; and
- amortisation of intangible assets.

Secondary Reporting – Geographical Segments

Geographic location:	Asia Pacific	North America	Europe	Total
2017	\$	\$	\$	\$
External sales revenue	4,004,747	21,296,496	24,025,731	49,326,974
Segment net profit/(loss) before tax	795,399	(1,795,451)	3,499,411	2,500,359
Unallocated expense items				(5,095,858)
Depreciation and amortisation	(605,722)	(469,600)	(156,989)	(1,232,311)
Impairment	(40,000)	-	-	(40,000)
Interest received				124,236
Interest paid				(20,422)
Loss before tax				(3,763,996)
Income tax expense				(399,335)
Loss after tax				(4,163,331)

SOMNOMED LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2017

18. SEGMENT OPERATIONS (continued)

Geographic location:	Asia Pacific	North America	Europe	Total
2016	\$	\$	\$	\$
External sales revenue	3,881,654	19,571,641	20,630,858	44,084,153
Segment profit before interest and tax	785,374	1,573,234	3,128,028	5,486,636
Unallocated expense items				(3,971,179)
Depreciation and amortisation	(508,271)	(394,318)	(117,465)	(1,020,054)
Impairment	(49,843)	-	-	(49,843)
Interest received				55,935
Interest paid				(10,723)
Profit before tax				490,772
Income tax expense				(423,587)
Profit after tax				67,185

19. PARTICULARS RELATING TO CONTROLLED AND ASSOCIATED ENTITIES

(a) Details of controlled entities are reflected below

Company	Country of Incorporation	Interest %	
		2017	2016
SomnoMed Limited	Australia		
Entities controlled by SomnoMed Limited			
SomCentre Pty Limited	Australia	100%	100%
SomnoMed, Inc.	USA	100%	100%
SomnoDent Pty Limited	Australia	100%	100%
SomnoMed Pte Ltd	Singapore	100%	100%
SomnoMed AG	Switzerland	100%	100%
SomnoMed Corporation Japan	Japan	100%	100%
SomnoMed Nordic AB	Sweden	100%	100%
SomnoMed Philippines Inc.	Philippines	100%	100%
SomnoMed Netherlands BV	Netherlands	100%	100%
SomnoMed France	France	92.9%	92.9%
Goedegebuure Slaaptechniek BV ¹	Netherlands	100%	87.5%
SomnoMed Germany GmbH	Germany	100%	100%
SomnoMed Service GmbH	Germany	100%	100%
SMH Biomaterial AG	Switzerland	100%	100%
SomnoMed Korea	South Korea	100%	100%
SomnoMed UK Limited	UK	100%	100%
SomnoMed Spain SL	Spain	100%	100%
SomnoMed Italy S.r.L.	Italy	100%	100%
SomnoMed Canada Inc.	Canada	100%	100%
SomnoMed Taiwan Limited Company	Taiwan	100%	100%
Renew Sleep Solutions, Inc. ²	USA	81.9%	81.9%
SomnoMed Finance, Inc.	USA	100%	100%

¹ Refer Note 19(b)

² Name changed from Sleep Centres America, Inc. on 2nd November 2016.

(b) Acquisition of Goedegebuure Slaaptechniek BV

In January 2012 SomnoMed Limited entered into a contract to acquire the Dutch oral appliance distribution company Goedegebuure Slaaptechniek B.V. with an upfront payment of 50% and the subsequent 50% to be paid over a period of 5 years in four annual portions commencing in 2014. In January 2017 SomnoMed Limited made a payment of \$208,369 (EUR 143,016) with 50% in cash and 50% in SomnoMed shares (27,938 shares at the price of \$3.74).

SOMNOMED LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2017

20. RECONCILIATION OF CASH	2017 \$	2016 \$
Cash at the end of the financial year as shown in the cash flow statement is reconciled to the related items in the balance sheet as follows:		
Cash at bank and on deposit and money market securities	14,210,321	17,632,252
	14,210,321	17,635,252

21. RECONCILIATION OF (LOSS)/PROFIT AFTER INCOME TAX TO NET CASH OUTFLOW FROM OPERATING ACTIVITIES

(Loss)/profit after income tax	(4,163,331)	67,185
Share and option expense	805,502	337,397
Impairment of goodwill	40,000	-
Impairment of capitalised development costs	-	49,843
Depreciation and amortisation	1,232,311	1,020,054
Net exchange differences	54,386	58,663
Change in operating assets and liabilities		
Increase in inventories	(343,437)	(385,100)
Increase in receivables	(2,545,227)	(736,406)
Increase in trade & other payables	1,916,121	1,476,709
Increase in provisions	819,934	205,658
(Increase)/decrease in deferred tax assets	(495,929)	11,020
Net cash (outflow)/inflow from operating activities	(2,679,670)	2,105,023

22. EARNINGS PER SHARE

Significant Accounting Policies

The Consolidated Entity presents basic and diluted earnings per share (EPS) for its ordinary shares. Basic EPS is calculated by dividing the net profit or loss attributable to equity holders of the parent for the financial period, after excluding any costs of servicing equity (other than ordinary shares) by the weighted average number of ordinary shares of the Company, adjusted for any bonus issue.

Diluted EPS is calculated using the basic EPS earnings as the numerator. The weighted average number of shares used as the denominator is adjusted by the after-tax effect of financing costs associated with the dilutive potential ordinary shares and the effect on revenues and expenses of conversion to ordinary shares associated with dilutive potential ordinary shares adjusted for any bonus issue.

	2017	2016
Net (loss)/profit used in calculating basic and diluted earnings per share	(3,343,878)	165,005
Basic profit per share (cents per share)	(6.23)	0.34
Diluted profit per share (cents per share)	(6.23)	0.32
Weighted average number of shares used in the calculation of basic earnings per share	53,657,916	48,623,946
Weighted average number of shares used in the calculation of diluted earnings per share	57,407,600	52,184,031
Shares on issue at year end per accounts	54,238,585	52,596,481
Number of options on issue at year end – each option is exercisable at between \$2.35 and \$3.78 per share and converts to one ordinary share	1,175,000	700,000

SOMNOMED LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2017

23. CAPITAL AND LEASING COMMITMENTS

2017 **2016**
\$ **\$**

Operating Lease Commitments

Non-cancellable operating leases contracted for but not capitalised in the financial statements

Payable

— not later than 1 year	2,110,762	790,168
— later than 1 year but not later than 5 years	5,967,597	2,768,683
— later than 5 years	1,636,322	1,942,433
	9,714,681	5,501,284

Included in the operating lease commitments are non-cancellable property leases with terms of between one year and ten years with, in some cases, options to extend (between three and five years). The leases have various escalation clauses. On renewal, the terms of the leases are renegotiated.

24. SHARE BASED PAYMENTS

(a) Movements in the number of share options held by employees are:

	2017	2016
	#	#
Opening balance	4,116,500	3,298,500
Exercised during the year	(1,014,166)	(60,000)
Shares issued and treated as options in these accounts (refer Note 15)	526,500	1,128,000
Shares issued and treated as options in previous accounts now treated as shares (refer Note 15)	-	(250,000)
Closing Balance	3,628,834	4,116,500

(b) Details of employee share options as at end of year:

Options granted to employees hold no voting or dividend rights and are not transferrable.

(c) Options

Shares treated as options in accounts (refer Note 15)	3,628,834	4,116,500
Exercised during the year	3,628,834	4,116,500

The options and shares issued under the Employee Share and Option plan outstanding at 30 June 2017 had a weighted average exercise price of \$3.08 (2016: \$2.13) and a weighted average remaining contractual life of 2.16 years (2016: 1.41 years). Exercise prices range from \$2.35 to \$3.78 in respect of options outstanding at 30 June 2017 (2016: \$1.23 to \$2.64 range).

The weighted average fair value of the options granted during the year was \$1.39 (2016: \$1.07).

This price was calculated by using a Black-Scholes option pricing model applying the following inputs:

	2017	2016
Weighted average exercise price	\$3.4812	\$2.4532
Weighted average life of the option	4.39 years	3.77 years
Underlying share price	\$3.39-\$3.78	\$2.67-\$2.74
Expected share price volatility	45.00	45.00
Risk free interest rate	2.50%	2.50%

**SOMNOMED LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2017**

24. SHARE BASED PAYMENTS (continued)

Historical volatility has been the basis for determining expected share price volatility as it is assumed that this is indicative of future trends, which may not eventuate.

Exercisability of the options has been considered when determining the fair value of the options.

The life of the options is based on the historical exercise patterns, which may not eventuate in the future.

Included under share and option expense in the statement of profit or loss and other comprehensive income is \$805,502 (2016: \$337,397), that relates, in full, to equity-settled share-based payment transactions.

(d) Shareholdings and Options and Rights Holdings held by Key Management Personnel, including options held in associated entities.

Please refer to the Remuneration Report.

(e) Share based payments

There were no other share-based payment arrangements in the year to 30 June 2017, other than shares and options issued to directors and executives pursuant to the Company's Executive Share and Option Plan as detailed in the Remuneration Report.

25. EVENTS SUBSEQUENT TO BALANCE DATE

Since the end of the financial year, the directors have not become aware of any matter that has significantly affected or may significantly affect the operations of the company in subsequent financial years.

26. RELATED PARTY DISCLOSURES

Related party transactions fall into the following categories:

(a) Controlled entities

Interests in controlled entities are disclosed in Note 19. The Company engages in transactions with its controlled entities, which are in ordinary course of business at arm's length on a transfer pricing basis.

	2017	2016
	\$	\$
The aggregate amount included in the profit before income tax for the Company that resulted from transactions with non-director related parties are:		
Royalties	1,464,631	4,310,203
Revenue from provision of services	818,993	779,888
Reimbursement of marketing expenses	(1,551,980)	-
Interest income	905,451	550,507
The aggregate amounts receivable from wholly-owned controlled entities by the Company at the reporting date are:		
Current receivables	29,905,077	28,383,871
Less impairment	(3,495,836)	(3,608,810)
	26,409,241	24,775,061

**SOMNOMED LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2017**

26. RELATED PARTY DISCLOSURES (continued)

(b) Director related entities

During the year consultancy fees of \$238,900 (2016: \$520,000) were paid/are payable to Belgove Pty Limited, a company associated with Dr Neustadt and consultancy fees of \$61,800 (2016: \$58,625) were paid to Leedoc Pty Limited, a company associated with Ms Ausburn (as per Director's remuneration).

(c) Transactions in securities of the Company

During the year directors or entities related to directors acquired under normal commercial terms shares or options in the Company as detailed in Note 24. Directors acquired these shares or options through the public offering, direct issue or on-market purchase.

	2017	2016
	\$	\$
(d) Loans to key management personnel		
Balance beginning of the year	570,500	570,500
Loans advanced	-	-
Loans repaid	(570,500)	-
Interest charged – advance	-	-
Interest received	-	-
Balance end of the year	-	570,500

Non-recourse advances to executives to acquire shares issued in the Company are not recorded in the Company's accounts and these shares are treated as options in these accounts in accordance with the Company's accounting policies and Australian Accounting Standards (Note 15). The total of such loans is reflected in Note 15. These loans were repayable the earlier of two years from the provision of the advances and the date the borrower ceased to be the legal owner of the shares.

27. KEY MANAGEMENT PERSONNEL COMPENSATION

(a) Names and positions held of Consolidated Entity and Company Key Management Personnel in office at any time during the financial year are:

Key Management Person

Derek Smith	Global Chief Executive Officer of SomnoMed Group (appointed 1 st September 2016)
Neil Verdal-Austin	Chief Financial Officer and Executive Vice President Asia Pacific
Jim Evanger	Chief Executive Officer of Renew Sleep Solutions, Inc. (appointed 1 st August 2016)
Kien Nguyen	Executive President – North America
Martin Weiland	Executive Vice President – Sales and Marketing Europe

(b) Compensation Practices and Key Management Personnel Compensation

Details of compensation practices and key management personnel compensation are disclosed in the Directors' Report, which accompanies these financial statements.

Details of management personnel compensation shares and options are disclosed in Note 24.

SOMNOMED LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2017

27. KEY MANAGEMENT PERSONNEL COMPENSATION (continued)

(b) Compensation Practices and Key Management Personnel Compensation (continued)

Compensation

The aggregate compensation made to directors and other members of key management personnel of the Consolidated Entity is set out below:

	2017	2016
	\$	\$
Short-term employee benefits	2,864,200	1,869,223
Post-employment benefits	34,770	31,350
Other	12,789	10,365
Share-based payments	713,692	227,974
	<u>3,625,451</u>	<u>2,138,912</u>

Mr Chris Bedford was a Key Management Person at 30 June 2016. During the year ended 30th June 2017, he was not considered a Key Management Person.

28. FINANCIAL INSTRUMENTS

Credit Risk

Significant Accounting Policies

Credit risk is the risk of financial loss to the Company or the Consolidated Entity if a customer, controlled entity or counterparty to a financial instrument fails to meet its contractual obligations and arises principally from the Company's and the Consolidated Entity's receivables from customers.

Trade and other receivables

The Company's and Consolidated Entity's exposure to credit risk is influenced mainly by the geographical location and characteristics of individual customers. The Consolidated Entity does not have a significant concentration of credit risk with a single customer.

Policies and procedures of credit management and administration of receivables are established and executed at a regional level. Individual regions deliver reports to management and the Board on debtor ageing and collection activities on a monthly basis.

In monitoring customer credit risk, the ageing profile of total receivables balances is reviewed by management by geographic region on a monthly basis. Regional management are responsible for identifying high risk customers and placing restrictions on future trading, including suspending future shipments and administering dispatches on a prepayment basis.

The Company and the Consolidated Entity have established an allowance for impairment that represents their estimate of incurred losses in respect of trade and other receivables.

Exposure to Credit Risk

The carrying amount of financial assets represents the maximum credit exposure. The maximum exposure to credit risk at the reporting date was:

	2017	2016
	\$	\$
Cash and equivalents	14,210,321	17,632,252
Trade receivables	6,618,529	6,059,483
Other receivables - current	1,825,350	962,749
	<u>22,654,200</u>	<u>24,654,484</u>

SOMNOMED LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2017

28. FINANCIAL INSTRUMENTS (continued)

Credit Risk (continued)

The maximum exposure to credit risk for trade and related party receivables at the reporting date by geographic region was:

	2017	2016
	\$	\$
North America	3,587,702	2,480,139
Europe	2,599,212	3,102,462
Asia Pacific	431,615	476,882
	<u>6,618,529</u>	<u>6,059,483</u>

Impairment Losses

The ageing of the trade receivables at the reporting date was:

Gross receivables

Past due 0 – 30	5,932,272	5,432,676
Past due 31 – 60	181,049	256,501
Past due 60 – 90	106,786	139,208
Past due 90 days and over	664,664	353,336
	<u>6,884,771</u>	<u>6,181,721</u>
Impairment	(266,242)	(122,238)
Trade receivables net of impairment loss	<u>6,618,529</u>	<u>6,059,483</u>

The movement in the allowance for impairment in respect of trade receivables during the year was as follows:

Balance at 1 July	(122,238)	(80,965)
Impairment movement	(145,564)	(37,524)
Exchange effect	1,560	(3,749)
Balance at 30 June	<u>(266,242)</u>	<u>(122,238)</u>

Impairment losses recognised in the year relate to significant individual customers, which have been assessed as impaired under the Consolidated Entity's accounting policy as detailed in Note 3(d).

Based upon past experience, the Consolidated Entity believes that no impairment allowance other than as provided in these accounts is necessary in respect of trade receivables not past due.

The allowance accounts used in respect of trade receivables are used to record impairment losses unless the Consolidated Entity is satisfied that non-recovery of the amount owing is possible; at that point, the amount considered non-recoverable is written off against the financial asset directly.

SOMNOMED LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2017

28. FINANCIAL INSTRUMENTS (continued)

Currency Risk

Significant Accounting Policies

The Consolidated Entity is exposed to currency risk on sales and purchases that are denominated in a currency other than the respective functional currencies of the controlled entities, primarily Australian dollars (AUD), but also United States dollars (USD), Euros (EUR), Swiss francs (CHF), Canadian dollars (CAD), Singapore dollars (SGD) and Japanese Yen (JPY). The currencies in which these transactions primarily are denominated are AUD, USD, CAD, EUR, CHF, SGD, JPY, GBP, SEK, NOK, NTD and Philippine Peso (PHP) and South Korean Won (KRW).

Over 93% (2016: 92%) of the Consolidated Entity's revenues and over 85% (2016: 86%) of costs are denominated in currencies other than AUD. Risk resulting from the translation of assets and liabilities of foreign operations into the Consolidated Entity's reporting currency is not hedged.

Consolidated Entity's exposure to foreign currency risk was as follows, based upon notional amounts:

Amounts local currency	KRW	GBP	PHP	JPY	USD	EUR	CHF	SEK	CAD	NOK	NTD
2017											
Cash and cash equivalents	16,328	31,861	658,675	26,779	4,035,819	3,861,202	24,505	95,383	36,497	95,775	14,796
Trade receivables	57,303	-	-	38,228	3,393,364	3,685,949	-	-	194,337	-	-
Trade payables	(2,431)	-	(727,596)	(36,920)	(980,956)	(2,013,141)	-	-	(20,499)	-	-
Gross balance sheet exposure	71,200	31,861	(68,921)	28,087	6,465,928	5,534,010	24,505	95,383	210,335	95,775	14,796
2016											
Cash and cash equivalents	15,036	21,010	54,216	31,058	5,543,240	4,164,973	-	357,752	51,206	100,355	-
Trade receivables	31,239	-	-	56,550	2,380,041	3,102,462	-	-	100,098	-	-
Trade payables	(2,816)	-	(580,885)	(33,481)	(752,858)	(1,567,926)	-	-	(19,076)	-	-
Gross balance sheet exposure	43,459	21,010	(526,669)	54,127	7,170,423	5,699,509	-	357,752	132,228	100,355	-

The following significant exchange rates applied to the Consolidated Entity during the year:

	Average Rate		Reporting date spot rate	
	2017	2016	2017	2016
AUD = 1				
USD	0.7532	0.7305	0.7687	0.7452
EUR	0.6880	0.6621	0.6732	0.6713
JPY	82.15	85.26	86.43	76.92
PHP	36.97	34.11	38.80	35.13
KRW	857.99	853.64	879.84	858.69
CAD	0.9977	0.9696	0.9966	0.9632

SOMNOMED LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2017

28. FINANCIAL INSTRUMENTS (continued)

Market Risk

Significant Accounting Policies

Market risk is the risk that changes in market prices such as foreign exchange rates, interest rates and equity prices will affect the Company's and the Consolidated Entity's net profit or loss or the value of its holdings of financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable parameters, while optimising the return.

Interest Rate Risk

Significant Accounting Policies

The effective interest method is used to allocate interest income or interest expense over the relevant period.

Profile

At the reporting date, the interest rate profile of the Consolidated Entity's interest bearing financial instruments was:

Carrying amount	2017	2016
Variable rate instruments	\$	\$
Financial assets	4,553,615	3,945,880

Liquidity Risk

Significant Accounting Policies

Liquidity risk is the risk that the Consolidated Entity will not be able to meet its financial obligations as they fall due. The Consolidated Entity's approach to managing liquidity is to ensure, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Consolidated Entity's reputation.

The Consolidated Entity monitors cash flow requirements and produces cash flow projections for the short and long term with a view to optimising return on investments. Typically, the Consolidated Entity ensures that it has sufficient cash on demand to meet expected operational net cash flows for a period of at least 30 days, including the servicing of financial obligations. This excludes the potential impact of extreme circumstances that cannot reasonably be predicted, such as natural disasters.

The following are the contractual maturities of the Consolidated Entity's financial assets and liabilities including estimated interest payments.

2017	Effective interest rate p.a.	Carrying amount \$	Less than 1 year	1-5 years	More than 5 years
Cash and cash equivalents	0.71%	14,210,321	14,210,321	-	-
Receivables	-	8,443,879	8,443,879	-	-
Payables	-	(5,779,646)	(5,779,646)	-	-
Total	-	16,874,554	16,874,554	-	-

2016	Effective interest rate p.a.	Carrying amount \$	Less than 1 year	1-5 years	More than 5 years
Cash and cash equivalents	0.72%	17,632,252	17,632,252	-	-
Receivables	-	7,022,232	7,022,232	-	-
Payables	-	(4,749,485)	(4,749,485)	-	-
Total	-	19,904,999	19,904,999	-	-

SOMNOMED LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2017

28. FINANCIAL INSTRUMENTS (continued)

Fair Values

The fair values of financial assets and liabilities, together with carrying amounts in the balance sheet are as follows:

	2017		2016	
	\$		\$	
Consolidated	Carrying amount	Fair value	Carrying amount	Fair value
Cash and equivalents	14,210,321	14,210,321	17,632,252	17,632,252
Trade and other receivables - current	8,443,879	8,443,879	7,022,232	7,022,232
Trade and other payables - current	(5,779,646)	(5,779,646)	(4,749,485)	(4,749,485)
Contingent consideration payable – current	-	-	(179,695)	(179,695)
Total	16,874,554	16,874,554	19,725,304	19,725,304

Basis for determining fair values

The following summarises the significant methods and assumptions used in estimating the fair values of financial instruments reflected in the table above.

Non-derivative financial assets and liabilities

The fair value of cash, receivables, payables and short-term borrowings is considered to approximate their carrying amount because of their short maturity.

Fair value hierarchy

The table below analyses financial instruments carried at fair value, by valuation method. The different levels have been defined as follows:

- Level 1: quoted prices (unadjusted) in active markets for identical assets and liabilities
- Level 2: inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (ie. as prices) or indirectly (ie. derived from prices).
- Level 3: inputs for the asset or liability that are not based on observable market data (unobvious inputs).

	Level 3	Total
30 June 2017		
Financial liabilities		
- Contingent consideration payable	-	-
30 June 2016		
Financial liabilities		
- Contingent consideration payable	179,695	176,695

There are no other financial instruments carried at fair value or valued using the above criteria.

Assets and liabilities held for sale are measured at fair value on a non-recurring basis.

There were no transfers between levels during the financial year.

The carrying amounts of trade and other receivables and trade and other payables are assumed to approximate their fair values due to their short-term nature.

Valuation techniques for fair value measurements categorised within level 3.

The fair value of financial liabilities is estimated by discounting the remaining contractual maturities at the current market interest rate that is available for similar financial liabilities.

The fair value of contingent consideration payable in relation to the Goedegebuure Slaaptechniek B.V. acquisition was based on an assessment of budgets and forecasts resulting in the fair value for the remaining 12.5% acquisition of the business.

SOMNOMED LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2017

28. FINANCIAL INSTRUMENTS (continued)

	2017	2016
	\$	\$
Contingent consideration payable		
Balance at beginning of year	179,695	1,059,575
Amount paid (Refer Note 19(b))	(208,369)	(453,642)
Net fair value loss/(gain)	32,551	(436,508)
Foreign currency translation difference	(3,877)	10,270
Balance at end of year	<u>-</u>	<u>179,695</u>

Sensitivity Analysis

In managing interest rate and currency risks, the Consolidated Entity aims to reduce the impact of short-term fluctuations on the Consolidated Entity's earnings. Over the longer term however, permanent changes in foreign exchange and interest rates will have an impact on the result.

For the year ended 30 June 2017, it is estimated that a general increase of one percent in interest rates would have decreased the Consolidated Entity's loss after income tax and equity by approximately \$185,000 and for the year ended 30 June 2016 the effect would have been to increase the Consolidated Entity's profit after income tax and equity by approximately \$94,000. A one percent decrease in interest rates would have had the equal but opposite effect on the Consolidated Entity's (loss)/profit and equity.

It is estimated that a general increase of ten percent in the value of the AUD against other foreign currencies would have increased the Consolidated Entity's loss for the year ended 30 June 2017, and decreased the Consolidated Entity's equity by approximately \$98,000. For the year ended 30 June 2016 the effect would have been to increase the Consolidated Entity's profit and increase the equity by \$335,000.

It is estimated that a general decrease of ten percent in the value of the AUD against other foreign currencies would have decreased the Consolidated Entity's loss for the year ended 30 June 2017, and increased the Consolidated Entity's equity by approximately \$120,000. For the year ended 30 June 2016 the effect would have been to increase the Consolidated Entity's (loss)/profit and increase the equity by \$410,000.

29. PARENT ENTITY DISCLOSURES

At and throughout the financial year ended 30 June 2017, the parent company was SomnoMed Limited, which has adopted the accounting policies consistent with those of the Consolidated Entity.

Result of the parent entity	2017	2016
	\$	\$
Net (loss)/profit	(3,736,948)	1,375,480
Other comprehensive income/(loss)	-	-
Total comprehensive income	<u>(3,736,948)</u>	<u>1,375,480</u>
Financial position of the parent entity at year end		
Current assets	6,454,065	8,453,978
Total assets	37,312,995	37,736,752
Current liabilities	921,999	799,453
Total liabilities	921,999	799,453
Total equity of the parent entity comprising of:		
Issued capital	46,937,359	44,552,216
Share option reserve	3,311,161	2,505,658
Accumulated losses	(13,857,523)	(10,120,575)
Total Equity	<u>36,390,997</u>	<u>36,937,299</u>

Parent entity contingencies

There are no contingent liabilities or future commitments in respect to the Parent Entity.

SOMNOMED LIMITED
ACN 003255221
DIRECTORS' DECLARATION

In the directors' opinion:

- the attached financial statements and notes thereto comply with the Corporations Act 2001, the Accounting Standards, the Corporations Regulations 2001 and other mandatory professional reporting requirements;
- the attached financial statements and notes thereto comply with International Financial Reporting Standards as issued by the International Accounting Standards Board as described in note 2 to the financial statements;
- the attached financial statements and notes thereto give a true and fair view of the Consolidated Entity's financial position as at 30 June 2017 and of its performance for the financial year ended on that date;
- there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable.

The directors have been given the declarations required by section 295A of the Corporations Act 2001.

Signed in accordance with a resolution of directors made pursuant to section 295(5)(a) of the Corporations Act 2001.

On behalf of the directors



Dr Peter Neustadt
Chairman

25th September 2017

INDEPENDENT AUDITOR'S REPORT

To the members of Somnomed Limited

Report on the Audit of the Financial Report

Opinion

We have audited the financial report of Somnomed Limited (the Company) and its subsidiaries (the Group), which comprises the consolidated statement of financial position as at 30 June 2017, the consolidated statement of profit and loss and other comprehensive income, the consolidated statement of changes in equity and the consolidated statement of cash flows for the year then ended, and notes to the financial report, including a summary of significant accounting policies **and the directors'** declaration.

In our opinion the accompanying financial report of the Group, is in accordance with the *Corporations Act 2001*, including:

- (i) **Giving a true and fair view of the Group's financial position as at 30 June 2017** and of its financial performance for the year ended on that date; and
- (ii) Complying with Australian Accounting Standards and the *Corporations Regulations 2001*.

Basis for opinion

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the ***Auditor's Responsibilities for the Audit of the Financial Report*** section of our report. We are independent of the Group in accordance with the *Corporations Act 2001* **and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 Code of Ethics for Professional Accountants** (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We confirm that the independence declaration required by the *Corporations Act 2001*, which has been given to the directors of the Company, would be in the same terms if given to the directors as at the **time of this auditor's report**.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key audit matters

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the financial report of the current period. These matters were addressed in the context of our audit of the financial report as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Carrying value of goodwill

As required by AASB 136 *Impairment of Assets*, goodwill is tested for impairment on an annual basis. The valuation of goodwill is significant to our audit because the balance of \$6,170,660 as at 30 June 2017 as disclosed in Note 12 is material to the financial statements.

The Group has tested goodwill allocated to each cash generating unit for impairment at reporting date by comparing the carrying value to its recoverable amount. The Group has determined recoverable amount through a value in use calculation for each cash generating unit using a discounted cash flow model, based on a five year projection period approved by management. This process is judgemental and is based on assumptions, specifically those in relation to revenue growth, costs incurred, and discount rates, which are affected by current and future market conditions.

Our audit procedures included, amongst others, evaluating the assumptions used in the discounted cash flow analysis. We applied a sensitivity analysis **on the Group's discounted cash flow models for each** cash generating unit to assess whether minor changes in the assumptions made would result in impairment. We also evaluated the adequacy of the disclosures about those assumptions to which the outcomes of the impairment test are most sensitive, that is, those that will have the most significant effect on the determination of the recoverable amount.

Recoverability of deferred tax assets

The valuation of the deferred tax asset is significant to our audit because of the material balance at year end of \$3,468,762 as disclosed in Note 7 and Note 2d, and the judgement surrounding the recoverability of the balance **and the complexity of the Group's** global business operations.

The Group has recorded deferred tax assets attributable to carry-forward tax losses of \$2,843,303 as at 30 June 2017. The recoverability of deferred tax assets is assessed through a judgemental process and is based on a variety of assumptions. The assumptions are in relation to potential future taxable profits, which is affected by future market conditions.

Our audit procedures included, amongst others, evaluating the assumptions used in forecasts to determine expected future profitability. We analysed the probability of recoupment which was determined based on future profitability. We have also assessed the disclosures with respect to deferred tax balances.

Other information

The directors are responsible for the other information. The other information comprises the information in the **Group's** annual report for the year ended 30 June 2017, but does not include the **financial report and the auditor's report thereon**.

Our opinion on the financial report does not cover the other information and we do not express any form of assurance conclusion thereon.



In connection with our audit of the financial report, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial report or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of the directors for the Financial Report

The directors of the Company are responsible for the preparation of the financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the financial report, the directors are responsible for assessing the ability of the group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

Auditor's responsibilities for the audit of the Financial Report

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free **from material misstatement, whether due to fraud or error, and to issue an auditor's report that** includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.

A further description of our responsibilities for the audit of the financial report is located at the Auditing and Assurance Standards Board website (<http://www.auasb.gov.au/Home.aspx>) at:

http://www.auasb.gov.au/auditors_responsibilities/ar1.pdf

This description forms part of our auditor's report.

Report on the Remuneration Report

Opinion on the Remuneration Report

We have audited the Remuneration Report included in the directors' report for the year ended 30 June 2017.

In our opinion, the Remuneration Report of Somnomed Limited, for the year ended 30 June 2017, complies with section 300A of the *Corporations Act 2001*.



Responsibilities

The directors of the Company are responsible for the preparation and presentation of the Remuneration Report in accordance with section 300A of the *Corporations Act 2001*. Our responsibility is to express an opinion on the Remuneration Report, based on our audit conducted in accordance with Australian Auditing Standards.

BDO East Coast Partnership

A handwritten signature in black ink, appearing to read 'Grant Saxon', written over a faint, light-colored BDO logo watermark.

Grant Saxon
Partner


Sydney, 25 September 2017

DECLARATION OF INDEPENDENCE BY GRANT SAXON TO THE DIRECTORS OF SOMNOMED LIMITED

As lead auditor of Somnomed Limited for the year ended 30 June 2017, I declare that, to the best of my knowledge and belief, there have been:

1. No contraventions of the auditor independence requirements of the *Corporations Act 2001* in relation to the audit; and
2. No contraventions of any applicable code of professional conduct in relation to the audit.

This declaration is in respect of Somnomed Limited and the entities it controlled during the period.



Grant Saxon
Partner

BDO East Coast Partnership

Sydney, 25 September 2017

ADDITIONAL INFORMATION

1. Shareholding

a. Distribution of Shareholders

Category (size of Holding)	Shareholders	Shares
1-1,000	650	229,694
1,001-5,000	559	1,403,305
5,001-10,000	176	1,289,426
10,001-100,000	228	5,847,186
100,001 and over	44	49,097,808
	1,657	57,867,419

b. The number of shareholdings held in less than marketable parcels is 251

c. The names of the substantial shareholders listed in the holding company's register as at 11 September 2017 are:

Shareholder	Number of Ordinary Shares	Percentage
TDM Asset Management Pty Ltd & Associates	8,850,032	15.29%
Dottie Investments Pty Ltd	4,647,002	8.03%
National Nominees Ltd as Custodian for Australian Ethical Smaller Companies Trust	4,085,407	7.06%
FIL Limited & Associates	3,176,791	5.49%

d. Voting Rights

Each ordinary share is entitled to one vote when a poll is called, otherwise each member present at a meeting or by proxy has one vote on a show of hands.

e. 20 Largest Shareholders — Ordinary Shares as at 11 September 2017

Name	No. of Ordinary Fully Paid Shares Held	% Held of Issued Ordinary Capital
1. HSBC Custody Nominees (Australia) Limited	16,529,024	28.564%
2. National Nominees Limited	7,074,611	12.226%
3. Dottie Investments Pty Ltd	4,647,002	8.030%
4. Smartequity EIS Pty Ltd	3,639,634	6.290%
5. Belgove Pty Ltd	2,275,705	3.933%
6. Ginga Pty Ltd	1,510,223	2.610%
7. Golden Words Pty Ltd	1,242,265	2.147%
8. Timbina Pty Ltd <Timbina Super Fund A/C>	1,081,876	1.870%
9. Bond Street Custodians Limited	941,601	1.627%
10. BNP Paribas Nominees Pty Ltd <Agency Lending DRP A/C>	794,102	1.372%
11. BNP Paribas Nominees Pty Ltd < DRP>	740,678	1.280%
12. J P Morgan Nominees Australia Limited	715,088	1.236%
13. Citicorp Nominees Pty Limited	708,446	1.224%
14. Mirrabooka Investments Limited	600,000	1.037%
15. R E M Medical Pty Ltd	531,394	0.918%
16. P Neustadt Holdings Pty Ltd	531,000	0.918%
17. BNP Paribas Nominees Pty Ltd <IB AU Noms Retail Client DRP>	410,648	0.710%
18. Thirty Sixth Vilmar Pty Ltd	356,560	0.616%
19. Honne Investments Pty Limited	350,000	0.605%
20. Tunend Pty Ltd	335,500	0.580%
	45,015,357	77.793%

CORPORATE DIRECTORY

Registered Office and Principal Place of Business

Level 3
20 Clarke St Crows Nest 2065
Telephone: (02) 9467 0400

Directors

Peter Neustadt	Non-executive Chairman
Lee Ausburn	Non-executive Director
Robert Scherini	Non-executive Director

Chief Executive Officer

Derek Smith

Chief Financial Officer

Neil Verdal-Austin

Company Secretary

Terence Flitcroft

Patent Attorneys

Spruson & Ferguson

Banker

Westpac Banking Corporation

Auditors

BDO East Cost Partnership

Share Registry

Boardroom Pty Limited
SYDNEY NSW 2000
(GPO Box 3993 Sydney NSW 2001)
Telephone (02) 9290 9600
Facsimile (02) 9279 0664
www.boardroomlimited.com.au

Company Website

www.somnomed.com.au

Stock exchange listing

SomnoMed Limited shares are listed on the Australian Securities Exchange (ASX code: SOM)